



Review

The coordination of nuclear and mitochondrial communication during aging and calorie restriction

Lydia W.S. Finley, Marcia C. Haigis*

The Paul F. Glenn Labs for the Biological Mechanisms of Aging, Department of Pathology, Harvard Medical School, Boston, MA 02115, USA

ARTICLE INFO

Article history:

Received 16 January 2009

Received in revised form 27 February 2009

Accepted 4 March 2009

Keywords:

Mitochondria

Aging

SIRT1

PGC-1 α

Metabolism

AMPK

ABSTRACT

Mitochondria are dynamic organelles that integrate environmental signals to regulate energy production, apoptosis and Ca²⁺ homeostasis. Not surprisingly, mitochondrial dysfunction is associated with aging and the pathologies observed in age-related diseases. The vast majority of mitochondrial proteins are encoded in the nuclear genome, and so communication between the nucleus and mitochondria is essential for maintenance of appropriate mitochondrial function. Several proteins have emerged as major regulators of mitochondrial gene expression, capable of increasing transcription of mitochondrial genes in response to the physiological demands of the cell. In this review, we will focus on PGC-1 α , SIRT1, AMPK and mTOR and discuss how these proteins regulate mitochondrial function and their potential involvement in aging, calorie restriction and age-related disease. We will also discuss the pathways through which mitochondria signal to the nucleus. Although such retrograde signaling is not well studied in mammals, there is growing evidence to suggest that it may be an important area for future aging research. Greater understanding of the mechanisms by which mitochondria and the nucleus communicate will facilitate efforts to slow or reverse the mitochondrial dysfunction that occurs during aging.

Published by Elsevier Ireland Ltd.

1. Introduction

Mitochondria are dynamic organelles that play critical roles in energy production, apoptosis, and intracellular signaling (Finkel and Holbrook, 2000; Wallace, 2005; Ryan and Hoogenraad, 2007). Mammalian tissues vary widely in mitochondrial number and bioenergetic capacity, and these parameters adapt in response to various physiological conditions, such as diet, exercise, temperature and hormones (Scarpulla, 2002). Mitochondria serve many metabolic roles, including ATP production, fatty acid oxidation, metabolism of acetyl-CoA by the tricarboxylic acid cycle, maintenance of intracellular calcium levels and biosynthesis of various molecules. Proper mitochondrial function is crucial for maintenance of homeostasis and engagement of appropriate stress responses both at the level of the cell and the entire organism. Not surprisingly, changes in mitochondrial number and activity are implicated in aging and age-related diseases, including diabetes, neurodegenerative diseases and cancer (Wallace, 2005).

Although mitochondria contain their own genome encoding 13 subunits involved in electron transport, the vast majority of the estimated 1000–1500 mitochondrial proteins are nuclear encoded (Johnson et al., 2007; Pagliarini et al., 2008). Mitochondrial biogenesis requires a sophisticated transcriptional program capable of responding to the energetic demands of the cell by coordinating expression of both nuclear and mitochondrial encoded genes (Scarpulla, 2002). Defects in regulation of mitochondrial biogenesis and gene expression leads to damaging consequences for the ability of the organism to cope with basal energetic demands or physiological stressors.

Mitochondria generate ATP through a process of oxidative phosphorylation (OXPHOS). As high-energy electrons derived from metabolic fuels are passed through a series of protein complexes (I–IV) embedded in the inner-mitochondrial membrane, their energy is used to pump protons from the mitochondrial matrix through the inner membrane into the inter-membrane space, generating a proton gradient known as the mitochondrial membrane potential ($\Delta\psi_m$) (Fig. 1). Ultimately, the electrons reduce oxygen to form water, and the protons flow down their gradient through ATP synthase, driving the formation of ATP from ADP. Alternatively, protons can flow through uncoupling proteins, dissipating their potential energy as heat. Reactive oxygen species (ROS), formed when electrons inappropriately combine with O₂ to form the highly reactive superoxide radical, are an inevitable

* Corresponding author at: Harvard Medical School, Department of Pathology, NRB 954, 77 Ave Louis Pasteur, Boston, MA 02115, USA. Tel.: +1 617 432 6865; fax: +617 342 6932.

E-mail address: marcia_haigis@hms.harvard.edu (M.C. Haigis).




Fig. 1. Mammalian mitochondrial retrograde signaling pathways. Mitochondrial activity can influence cellular NAD⁺/NADH ratios, cytosolic free Ca²⁺ concentrations, ATP/ADP ratios and cellular oxidative stress. Electrons from cytosolic NADH can be transferred to mitochondrial NAD⁺ to form NADH via the malate–aspartate shuttle (1 and 2). This NADH, along with the NADH generated by the TCA cycle, donates electrons to complex I of the mitochondrial electron transport chain, regenerating NAD⁺. Electrons are passed between the complexes of OXPHOS (I, II, III and IV) and their energy is used to pump protons into the intermembrane space. Complex V uses this proton gradient to synthesize ATP, which is then exchanged for cytosolic ADP by ANT (5). Small molecules, such as ADP, ATP and Ca²⁺ diffuse cross the outer mitochondrial membrane through VDAC. Mitochondrial membrane potential drives Ca²⁺ entry into the matrix through a Ca²⁺ uniporter (3), and Ca²⁺ is transferred out through an antiporter that exchanges Na⁺/H⁺ for Ca²⁺ (4). Ca²⁺ can stimulate activity of three enzymes in the TCA cycle, resulting in increased electron transport. Electrons can leak out of the electron transport chain at complexes I and III, combining with O₂ to form superoxide, which can be converted by SOD2 to H₂O₂ or combine with NO to form ONOO⁻. Superoxide, ONOO⁻ and H₂O₂ can all cause oxidative damage, and H₂O₂ can diffuse out of the mitochondria to cause oxidative stress and trigger redox signaling. Ca²⁺ is required for synthesis of NO, and NO can inhibit complex IV, increasing electron leakage. Each of these outputs (shown in green) can act as signaling molecules and influence the activity of various signaling pathways with the potential to regulate transcription of mitochondrial genes. Increases in the NAD/NADH ratio are thought to activate SIRT1, which can deacetylate and activate PGC-1α. Increased cytosolic Ca²⁺ triggers a signaling cascade that increases phosphorylation of CREB, stimulating its ability to activate transcription of the PGC-1α gene. A rise in the ADP/ATP ratio activates AMPK, which can inhibit mTORC1 activity by phosphorylation of TSC2 and raptor. AMPK also phosphorylates and activates PGC-1α. mTORC1 itself can interact with PGC-1α and YY1 to stimulate transcription of mitochondrial genes. Finally, changes in cellular redox state, whether by changes in the NAD⁺/NADH ratio or increased oxidant production, can activate several redox signaling cascades. (1) Malate – α-ketoglutarate transporter, (2) glutamate – aspartate transporter, (3) calcium uniporter, (4) Na⁺/H⁺ – dependent Ca²⁺ antiporter and (5) adenine nucleotide translocator (ANT).

byproduct of this process (Wallace, 2005). An increase in $\Delta\psi_m$, whether caused by impaired OXPHOS or an overabundance of nutrients relative to ADP, will stall electrons in the early steps of the electron transport chain and result in elevated ROS production (Wallace, 2005). SOD2 converts mitochondrial superoxide to hydrogen peroxide, which can then diffuse out of the mitochondria. ROS react with lipids, protein and DNA to generate oxidative damage, and so cells must guard carefully against an increase in oxidative stress accompanying ROS production.

Mitochondria are the primary site of ROS production within the cell, and increased oxidative stress is proposed to be one of the causes of mammalian aging (Harman, 1956; Finkel and Holbrook, 2000; Wallace, 2005). As a result, there is much interest in mitochondrial bioenergetic changes that occur with aging, and the topic has been extensively scrutinized (Merry, 2004; Hunt et al., 2006; Navarro and Boveris, 2007). Major mitochondrial age-related changes are observed in multiple tissues and include decreased $\Delta\psi_m$, increased ROS production and an increase in

oxidative damage to mtDNA, proteins and lipids (Sastre et al., 1996; Hagen et al., 1997; Bevilacqua et al., 2005; Short et al., 2005).

Importantly, many of these changes can be mitigated or prevented by the dietary regimen of calorie restriction (CR) (Merry, 2002; Merry, 2004; Hunt et al., 2006). CR extends the lifespan of a wide variety of organisms, from yeast to rodents. In higher organisms, CR reduces the incidence of age-related diseases such as diabetes, cancer and cardiovascular disease (Loeb and Northrop, 1917; Comfort, 1963; Weindruch and Walford, 1988; McCay et al., 1989; Lin et al., 2002b; Bordone and Guarente, 2005; Haigis and Guarente, 2006). Although the molecular mechanisms by which CR exerts its anti-aging effects remain unknown, its beneficial impact on mitochondrial function is well established. Studies in rodents and using cell culture models of CR illustrate that CR causes a decrease in ROS production and attenuates the accrual of age-related oxidative damage, especially in postmitotic tissues such as brain, heart and skeletal muscle (Sohal et al., 1994; Sohal and Weindruch, 1996; Gredilla et al., 2001; Sanz et al., 2005; Lopez-Lluch et al., 2006). There is also evidence that CR may increase mitochondrial turnover in the liver, facilitating the removal of damaged mitochondria (Miwa et al., 2008).

The effects of CR on mitochondrial respiratory function and ATP generation are quite controversial (Hunt et al., 2006). Several studies in rodents suggest that CR can block an age-related decline in OXPHOS enzyme activity in skeletal muscle and can increase mitochondrial respiration in white adipose tissue (WAT) (Nisoli et al., 2005; Baker et al., 2006; Hepple et al., 2006). However, Lambert et al. (2004) studied rats on a CR diet for 4.5 and 15 months and found no change in the respiration rate of mitochondria from liver, heart, brain or kidney, although the authors did see an increase in respiration in brown adipose tissue. Other studies have shown that CR for 2, 6 and 12 months, but not for 18 months, decreases mitochondrial oxygen consumption in skeletal muscle (Bevilacqua et al., 2004; Bevilacqua et al., 2005). Such discrepancies could be due to differences in diet or experimental protocol, tissue-specific effects, or subtle changes in the physiological state of the animal at the time of the experiment. The relationship between mitochondrial OXPHOS activity and longevity is equally controversial. Some studies have found that CR in yeast increases mitochondrial respiration, and that respiration is required for CR-induced longevity (Lin et al., 2002b; Easlon et al., 2007), although another report did not observe this requirement (Kaeberlein et al., 2005a). CR also increases mitochondrial respiration in worms, although paradoxically, knock-down of a large number of genes critical for mitochondrial function extends lifespan in worms (Lee et al., 2003; Bishop and Guarente, 2007). Clearly, more work needs to be done to address how changes in mitochondrial function affect aging and longevity.

Transcriptional profiles of skeletal muscle, white adipose tissue, kidney, brain and heart consistently show a decrease in expression of mitochondrial genes with age (Lu et al., 2004; Zahn et al., 2006; Linford et al., 2007; Melov et al., 2007). At the same time, mitochondrial turnover may be reduced, resulting in an age-related accumulation of old, damaged, or non-functional mitochondria (Terman, 2006). A study comparing transcriptional profiles of humans, mice, flies and worms found that genes involved in OXPHOS were downregulated during aging in all four organisms, suggesting that these genes represent a conserved marker of aging (Zahn et al., 2007). Additionally, transcriptional profiling and analysis of mitochondrial content have demonstrated that CR can stimulate mitochondrial biogenesis and increase the expression of mitochondrial enzymes involved in OXPHOS (Lambert et al., 2004; Nisoli et al., 2005; Lopez-Lluch et al., 2006; Civitarese et al., 2007). Many studies show that fatty acid oxidation in rodents and humans declines in a variety of tissues

with age, and that this decline can be linked to an age-dependent increase in fat accumulation (Abu-Ereish et al., 1977; Melanson et al., 1997; Tucker and Turcotte, 2002; Park et al., 2006; Solomon et al., 2008). CR can prevent an age-related decline in the expression of genes involved in fatty acid oxidation (Lee et al., 2002; Zhu et al., 2004).

Given the grave consequences of mitochondrial dysfunction seen during aging and in age-related disease, including falling ATP production, increased ROS generation and accumulation of oxidatively damaged macromolecules, it is crucial to understand the signaling pathways that regulate mitochondrial number and function. Communication between the nucleus and mitochondria is essential for maintenance of appropriate mitochondrial activity, and disruption of this coordination often accompanies aging and age-related disease. In this review, we will address major signaling pathways between the nucleus and mitochondria that are responsible for regulating mitochondrial number, fuel utilization and energy production, and how this regulation is affected by aging and age-related diseases.

2. Transcriptional pathways controlling mitochondrial function

2.1. PGC-1 α

Several transcription factors play a role in the regulation of mitochondrial gene expression. For example, mitochondrial transcription factor A (TFAM) is responsible for transcription of genes encoded by mtDNA and is essential for mtDNA maintenance (Scarpulla, 2008). Although there is no single nuclear transcription factor responsible for coordinated expression of all genes encoding mitochondrial proteins, the binding sites of several transcription factors, including Sp-1, YY-1, CREB, MEF-2/E-box, and the nuclear respiratory factors NRF-1, NRF-2, ERR α , REBOX/OXBOX and MT1-4, are common in nuclear-encoded mitochondrial gene promoters (Goffart and Wiesner, 2003; Scarpulla, 2008). Since none of these transcription factors alone can account for the regulation of most mitochondrial proteins, coordinated changes in nuclear-encoded mitochondrial gene expression likely requires integration of multiple transcriptional pathways, a feat achieved largely by the peroxisome-proliferator-activated receptor γ coactivator-1 (PGC-1) family of transcriptional coactivators. PGC-1 coactivators interact with chromatin modifying enzymes, basal transcription machinery and splicing factors and trigger a robust induction of transcriptional activity (Handschin and Spiegelman, 2006). Members of the PGC-1 family, PGC-1 α , PGC-1 β and PRC, have emerged as master transcriptional regulators of mitochondrial function. Although PGC-1 β has been shown to exert powerful effects on mitochondrial biogenesis and function, including regulating genes involved in fatty acid oxidation and ROS scavenging (Lin et al., 2003a; St-Pierre et al., 2003; Arany et al., 2007), PGC-1 α is the best studied of this coactivator family.

PGC-1 α was originally identified as a transcriptional regulator of PPAR γ capable of stimulating UCP-1 expression in brown adipose tissue (Puigserver et al., 1998). Subsequently, PGC-1 α has been shown to coactivate a number of nuclear receptors, including PPARs, HNF4 α , GR and ERR α , in addition to transcription factors such as NRF-1, MEF2C, FOXO1 and YY1 (Handschin and Spiegelman, 2006; Rodgers et al., 2008). This wide variety of binding partners empowers PGC-1 α to induce context-specific coordinated sets of gene expression that are tailored to the immediate physical demands of the organism. Moreover, the ability of PGC-1 α to coactivate major transcription factors involved in mitochondrial gene expression, including NRF-1, NRF-2, ERR α and PPAR α , endows PGC-1 α with the ability to direct the complex program of mitochondrial biogenesis (Handschin and Spiegelman, 2006;

Ryan and Hoogenraad, 2007). By coactivating NRF-1 directly on the promoters of TFAM and mitochondrial transcription specificity factors TFB1M and TFB2M, PGC-1 α ensures the coordination of nuclear and mitochondrial genomes during biogenesis (Wu et al., 1999; Gleyzer et al., 2005). Consistent with its role as a master-regulator of mitochondrial biogenesis, PGC-1 α expression closely correlates with mitochondrial content and is induced by cold exposure, short-term exercise and fasting—all conditions that increase tissue demands on mitochondrial function (Kelly and Scarpulla, 2004). Indeed, overexpression of PGC-1 α in skeletal muscle, white adipose cells and the heart is sufficient to induce mitochondrial biogenesis, elevate oxygen consumption and increase fatty acid oxidation (Puigserver et al., 1998; Wu et al., 1999; Lin et al., 2002a; Kelly and Scarpulla, 2004; Russell et al., 2004).

Given the apparent decline in mitochondrial biogenesis and function during aging, it is important to understand how PGC-1 α activity changes with age. Several lines of evidence link PGC-1 α and aging: expression of PGC-1 α is regulated by aging; PGC-1 α is capable of improving or rescuing mitochondrial dysfunction, and PGC-1 α is implicated in the pathogenesis of several age-related diseases, including diabetes, heart failure and neurodegeneration. First, PGC-1 α levels decline with age in rodent skeletal muscle and this decline is blunted by CR (Baker et al., 2006; Hepple et al., 2006). Human subjects engaged in CR or CR plus exercise demonstrated increased PGC-1 α levels (Civitarese et al., 2007). A cell culture model of CR, in which cells were cultured with serum from calorie restricted humans or rats, similarly induced increased PGC-1 α expression (Lopez-Lluch et al., 2006; Civitarese et al., 2007; Allard et al., 2008). Furthermore, several genetic models of longevity show increased levels of PGC-1 α accompanied by improvements in mitochondrial function. Fat-specific insulin receptor knock-out (FIRKO) mice have an increased lifespan in addition to elevated levels of PGC-1 α and PGC-1 β and increased mitochondrial DNA content in white adipose tissue (Katic et al., 2007). While expression of nuclear-encoded mitochondrial genes tends to decline with age in the white adipose tissue of the control mice, expression of these genes is maintained, or even increased, in the long-lived FIRKO mice (Katic et al., 2007). Likewise, long-lived growth hormone receptor knock-out mice have higher levels of PGC-1 α than their controls, while bovine growth hormone transgenic mice have reduced levels of PGC-1 α and shortened lifespan (Al-Regaiey et al., 2005). Taken together, these studies suggest that modulation of mitochondrial function by PGC-1 α may play an important role in lifespan regulation.

Second, PGC-1 α improves mitochondrial dysfunction, a major phenotype of aging and age-related diseases. The biological changes effected by exercise provide an important example of the ability of PGC-1 α to exert anti-aging benefits through a program of mitochondrial biogenesis. Exercise increases skeletal muscle mitochondrial number and enzyme activity (Holloszy and Booth, 1976). Moreover, exercise mitigates the age-related decline of both of these parameters in skeletal muscle (Short et al., 2003; Menshikova et al., 2006; Conley et al., 2007). For example, compared with young subjects, the gene expression profile of elderly subjects showed striking downregulation of genes involved in mitochondrial function. Six months of strength training reversed many of these transcriptional changes, particularly for genes encoding mitochondrial proteins (Melov et al., 2007). Similarly, skeletal muscle mitochondrial ATP production was improved by exercise in elderly subjects (Jubrias et al., 2001; Williams et al., 2007). The mitochondrial benefits of exercise may be mediated in large part by PGC-1 α ; indeed, many studies have documented an increase in PGC-1 α levels following both acute exercise and exercise training, although the exercise-induced increase in PGC-1 α is enhanced by prior training (Goto et al., 2000; Baar et al., 2002; Pilegaard et al., 2003; Russell et al., 2003; Terada et al., 2005;

Winder et al., 2006). Consistent with this hypothesis, mice with muscle-specific PGC-1 α overexpression display improved performance in a variety of exercise challenges in addition to increased mitochondrial gene expression, mtDNA content, and enzyme activity (Calvo et al., 2008). Moreover, transgenic overexpression of PGC-1 α in the skeletal muscle of a mouse model of mitochondrial myopathy resulted in increased mitochondrial biogenesis and improved ATP levels and was sufficient to improve clinical symptoms and prolong lifespan (Wenz et al., 2008).

Many studies suggest that mitochondrial dysfunction is associated with age-related diseases such as diabetes (Lowell and Shulman, 2005). For example, insulin-resistant offspring of patients with type 2 diabetes have reduced muscle mitochondrial density and substrate oxidation (Petersen et al., 2004; Morino et al., 2005). Additionally, a study by Petersen et al. (2003) showed that elderly subjects had a marked increase in insulin resistance in muscle accompanied by decreases in mitochondrial substrate oxidation and ATP synthesis. Gene expression changes corroborate these observations: expression of genes involved in OXPHOS is reduced in diabetic patients, their first-degree family members and individuals with glucose intolerance (Mootha et al., 2003; Patti et al., 2003). The same studies showed that PGC-1 α (and PGC-1 β) expression levels were also decreased, suggesting that a decline in PGC-1-mediated coactivation of transcription of genes encoding mitochondrial proteins is a major cause of the decline in mitochondrial number and function during diabetes (Mootha et al., 2003; Patti et al., 2003). Supporting this hypothesis, Mootha et al. (2004) demonstrated that PGC-1 α regulates OXPHOS gene expression through induction and coactivation of ERR α and NRF-2, and that disruption of this interaction in cultured muscle cells elicits some aspects of a type 2 diabetes-like phenotype. A pair of recent studies challenge the model that decreased PGC-1 α expression plays a causal role in the development of diabetes. PGC-1 α skeletal muscle-specific knockout mice show normal peripheral insulin sensitivity and conversely, transgenic mice overexpressing PGC-1 α in muscle are more prone to insulin resistance (Handschin et al., 2007; Choi et al., 2008). It will be important for future studies to examine how specific changes in mitochondrial function affect the pathogenesis of diabetes. Since both PGC-1 α and PGC-1 β expressions in skeletal muscle decrease with age, PGC-1 α may serve as an important bridge that links age-related decline in mitochondrial function with a concurrent increase in the incidence of type 2 diabetes (Ling et al., 2004).

Cardiovascular disease is another hallmark of aging, and PGC-1 α has been linked to the pathogenesis of heart failure (Finck and Kelly, 2006; Handschin and Spiegelman, 2006). PGC-1 α is decreased in some forms of heart failure that are associated with a decrease in fatty acid oxidation and an increased reliance on glucose oxidation (Huss and Kelly, 2004, 2005). For example, in mouse models of chronic pressure overload (a model for hypertension), PGC-1 α and PPAR α target genes are downregulated (Finck and Kelly, 2006). End-stage heart failure is often associated with reduced mitochondrial respiration and ATP production, and PGC-1 α null mice display both of these characteristics (Arany et al., 2005; Huss and Kelly, 2005). Hearts from mice deficient of PGC-1 α have an impaired ability to increase work output in response to stimulation and display an age-dependent increase in cardiac dysfunction (Arany et al., 2005). However, chronic cardiac-specific overexpression of PGC-1 α causes mitochondrial proliferation that ultimately results in ultrastructurally abnormal mitochondria and cardiomyopathy (Lehman et al., 2000; Russell et al., 2004). Thus, although increased PGC-1 α expression may not prove a panacea for all diseases of aging, there is much evidence to suggest that falling PGC-1 α levels may play a role in age-related heart failure.

Several studies suggest a link between PGC-1 α and neurodegeneration. Impaired mitochondrial function, including decreased

expression of genes involved in OXPHOS, is linked to a number of neurodegenerative diseases such as Parkinson's, Alzheimer's and Huntington's disease (HD) (Schon and Manfredi, 2003). Mice lacking PGC-1 α display behavioral changes and neurodegeneration, including lesions in the striatum, the primary brain region affected by HD (Lin et al., 2004a; Leone et al., 2005). More direct evidence of a role for PGC-1 α in HD was provided by Cui et al., who showed that mutant huntingtin can directly interfere with transcription of PGC-1 α , triggering mitochondrial dysfunction (Cui et al., 2006). Exogenous PGC-1 α can partially reverse the deleterious effects of mutant huntingtin in cultured cells, and lentiviral-mediated overexpression of PGC-1 α in the striatum is neuroprotective in a transgenic model of HD (Cui et al., 2006). Furthermore, mitochondria from HD mouse brain show reduced PGC-1 α levels, OXPHOS gene expression and oxygen consumption, and stable expression of PGC-1 α increases the resistance of mutant neurons to mitochondrial toxins (Weydt et al., 2006). Increased PGC-1 α expression has also been shown to reduce neuronal cell death due to oxidative stress (St-Pierre et al., 2006). This study found that PGC-1 α null mice are hypersensitive to neurodegeneration triggered by oxidative stressors such as MPTP and kainic acid, and that induction of anti-oxidant genes requires PGC-1 α activity (St-Pierre et al., 2006). With the ability to increase mitochondrial biogenesis, function and anti-oxidant defenses, PGC-1 α is powerfully equipped to combat many of the suspected causes of aging and age-related decline.

While changes in PGC-1 α expression have an important impact on mitochondrial number and bioenergetics, PGC-1 α is subject to a wide variety of regulatory mechanisms, including subcellular localization, turnover and post-translational modification, all of which have important consequences for its activity (Handschin and Spiegelman, 2006). A study by Anderson et al. (2008) suggested a model in which all of these mechanisms of regulation converge to form a transcriptional response tailored to specific physiological conditions. In their model, PGC-1 α is found in both the nucleus and the cytoplasm under basal conditions, and translocates to the nucleus during stress. Nuclear SIRT1 deacetylates and activates PGC-1 α at the same time that GSK3 β phosphorylates PGC-1 α , priming it for ubiquitination and degradation. The net result is transient PGC-1 α activity, enabling a rapid transcriptional stress response that is quickly shut off by subsequent degradation of the coactivator. Under chronic stress conditions such as CR, however, GSK3 β does not phosphorylate PGC-1 α , and PGC-1 α is thus perpetually active in the nucleus, facilitating a sustained increase in transcription of genes involved in mitochondrial function (Anderson et al., 2008). In this manner, post-translational regulation provides an additional mechanism whereby PGC-1 α can regulate mitochondrial function according to the specific needs of the cell.

2.2. SIRT1

Conserved from bacteria to mammals, sirtuins are a family of proteins that regulate metabolism and longevity in a variety of model organisms (Table 1) (Haigis and Guarente, 2006; Schwer and Verdin, 2008). Sirtuins are protein deacetylases and/or ADP-ribosyltransferases whose absolute requirement for NAD⁺ suggests that their activity may be tied to the metabolic state of the cell (Guarente, 2006; Schwer and Verdin, 2008). In yeast, increased dosage of silent information regulator 2 (Sir2) extends lifespan by 50% while Sir2 deletion shortens lifespan, and some studies demonstrate that lifespan extension by CR requires Sir2 (Kaeberlein et al., 1999; Lin et al., 2000). Similarly, increased levels of Sir2 extend lifespan in worms and flies (Tissenbaum and Guarente, 2001; Rogina and Helfand, 2004). Of the seven mammalian sirtuins (SIRT1–7), SIRT1 is most closely related to yeast Sir2 and the best

Table 1

Summary of role of major mitochondrial regulators on lifespan and aging.

	Mitochondrial function	lifespan			Mammalian aging	Mammalian CR
		Yeast	Worms	Flies		
PGC-1 α	↑	?	?	?	↓	↑
SIRT1	↑	↑	↑	↑	↓	↑
AMPK	↑	↓	↑	?	↓	No change
mTOR	↑	−↑	−↑	−↑	?	?

Arrows indicate that a given protein is involved in the corresponding process. All four proteins are capable of increasing measures of mitochondrial function, including mitochondrial number, OXPHOS capacity or fatty acid oxidation. Expression of the SIRT1 ortholog, Sir2, increases lifespan in yeast, worms and flies; AMPK increases lifespan in worms but decreases yeast lifespan, and inhibition of mTOR increases lifespan in all three model organisms. For mammalian aging and CR, arrows indicate how a given protein's expression or activity changes.

studied to date (Frye, 2000; Bordone and Guarente, 2005). Through deacetylation of a variety of proteins, including PGC-1 α , FOXO1, FOXO3, Ku70, NF- κ B, AceCS1, MEF2 and p53, SIRT1 can regulate physiological processes, such as stress resistance and energy metabolism, that are known to be affected during aging and moderated by CR (Haigis and Guarente, 2006; Schwer and Verdin, 2008).

Intriguingly, mammalian sirtuins have diverse subcellular localizations, raising the possibility that sirtuins may provide a mechanism for inter-organelle coordination under various stress conditions (Michishita et al., 2005). SIRT1, SIRT6 and SIRT7 are found predominantly in the nucleus; SIRT3, SIRT4 and SIRT5 localize to mitochondria, and SIRT2 is cytoplasmic (Michishita et al., 2005). Growing evidence suggests that sirtuins may shift localization in response to specific signals. SIRT3 may translocate from the mitochondria to the nucleus during cellular stress, and both SIRT1 and SIRT2 shuttle between the nucleus and cytoplasm (North and Verdin, 2007; Scher et al., 2007; Tanno et al., 2007; Nakamura et al., 2008). In addition, sirtuins likely orchestrate inter-organelle communication independent of physical shuttling. For example, SIRT3 overexpression results in increased levels of phospho-CREB, which may result in numerous transcriptional changes, including elevated PGC-1 α transcription (Shi et al., 2005). It will be interesting to see if changes in the activity of mitochondrial sirtuins can influence signaling pathways outside of the mitochondria. Furthermore, although SIRT1 physically binds nuclear and cytosolic proteins, its activity has profound effects on mitochondrial number and oxidative capacity (Haigis and Guarente, 2006; Schwer and Verdin, 2008).

There are few studies directly linking SIRT1 to mammalian aging, but evidence suggests that SIRT1 may be a pro-longevity factor. SIRT1 expression seems to mirror the proliferative state of the cell: SIRT1 levels decline as cells senesce but are restored with immortalization (Sasaki et al., 2006). Similarly, SIRT1 protein expression decreases with age in tissues which mitotic activity declines over time, but tissues with constant mitotic activity demonstrate no change in SIRT1 levels (Sasaki et al., 2006). SIRT1 activity, but not protein levels, decline with age in pancreatic β cells, and this may be due to a decline in systemic NAD⁺ biosynthesis (Ramsey et al., 2008). It will be interesting to see if this systemic decline in NAD⁺ biosynthesis translates into lower SIRT1 activity in a variety of tissues. A recent study by Oberdoerffer et al. (2008) suggests that SIRT1 represses repetitive DNA and thus may promote genomic stability in mammalian cells in a manner analogous to that of yeast Sir2. Loss of SIRT1 repression results in

transcriptional changes that are similar to those seen during aging in the brain, and overexpression of SIRT1 can suppress these age-dependent transcriptional changes (Oberdoerffer et al., 2008). A fraction of the genes regulated by SIRT1 may encode mitochondrial proteins, and so it will be interesting to see how changes in regulation of genomic stability by SIRT1 affect mitochondrial function.

CR data from rodents support the hypothesis that SIRT1 is a conserved mediator of several benefits of CR. Several groups have found that CR upregulates SIRT1 expression in a variety of tissues, such as brain, kidney, liver, white adipose tissue and skeletal muscle, although the effects of CR on SIRT1 expression remain controversial and may be tissue specific (Cohen et al., 2004; Nisoli et al., 2005; Civitarese et al., 2007; Barger et al., 2008; Chen et al., 2008). Consistent with the idea that SIRT1 may be responsible for some of the benefits of CR, transgenic mice overexpressing SIRT1 display several similarities with CR mice. Whole body SIRT1 knock-in mice are leaner, more glucose tolerant, and displayed reduced levels of blood cholesterol, adipokines and insulin compared to WT controls (Bordone et al., 2007). A separate model of SIRT1 overexpression found that increased levels of SIRT1 do not improve basal glucose tolerance, but are protective against obesity-induced glucose intolerance (Banks et al., 2008). Additionally, while CR causes an increase in activity in WT mice, restricted SIRT1 null mice do not increase their activity, suggesting that SIRT1 is necessary for this phenotype of CR (Chen et al., 2005; Boily et al., 2008). Moreover, CR was not able to increase the lifespan of SIRT1 null mice, although the short lifespan of SIRT1 null mice complicate the interpretation of this observation (Boily et al., 2008; Li et al., 2008). Furthermore, adipose tissue size and distribution change with age, and a reduction in white adipose tissue mass is presumed to be responsible for at least part of the lifespan increase by CR (Blüher et al., 2003; Cartwright et al., 2007). SIRT1 has been shown to bind PPAR γ and repress transcription of its target genes involved in fat storage (Picard et al., 2004). As a result, upregulation of SIRT1 in differentiated fat cells causes lipolysis and fat loss, suggesting that an increase in SIRT1 levels in WAT during CR may be in part responsible for increased mobilization of fatty acids and reduced adiposity (Picard et al., 2004).

Several studies lead to the conclusion that SIRT1 exerts its control over mitochondrial number and fuel oxidation primarily by regulating PGC-1 α activity. Rodgers et al. (2005) showed that in the fasted liver, SIRT1 interacts with and deacetylates PGC-1 α , enabling a transcriptional switch from glycolytic to gluconeogenic gene expression and enhancing hepatic glucose output. Subsequent studies have shown that SIRT1 can orchestrate a coordinated shift in mitochondrial substrate usage, allowing the cell to preserve glucose while oxidizing fatty acids, reminiscent of the substrate switch seen during CR. In skeletal muscle, deacetylation of PGC-1 α by SIRT1 promotes transcription of mitochondrial fatty acid oxidation genes, and SIRT1 is required for the switch to fatty acid oxidation under low-glucose conditions (Gerhart-Hines et al., 2007). Additionally, this study found that deacetylation of PGC-1 α by SIRT1 produces an increase in transcription of genes involved in OXPHOS, suggesting that under certain conditions, SIRT1 can have an important impact on mitochondrial substrate oxidation and energy production (Gerhart-Hines et al., 2007). Consistently, mitochondria isolated from livers of SIRT1 null mice displayed lower rates of respiration and ROS production (Boily et al., 2008). Indeed, compared to WT counterparts, SIRT1 null mice had increased levels of active AMP-activated protein kinase (AMPK) after a 24-h fast, implying that the SIRT1 null mice have difficulty maintaining ATP levels (Boily et al., 2008). Together, these studies suggest that SIRT1 is necessary for appropriate mitochondrial substrate oxidation during energy depletion.

Pharmacological activators also support a role for SIRT1 in the control of mitochondrial function. Resveratrol, a naturally occurring polyphenol, was identified in a screen for SIRT1 activators and has subsequently been shown to increase lifespan and delay aging in worms and flies in a Sir2-dependent manner (Howitz et al., 2003; Wood et al., 2004; Viswanathan et al., 2005). Resveratrol can increase survival of mice fed a high-calorie diet, and although it does not increase lifespan of mice fed a standard chow diet, resveratrol does reduce the severity of physical hallmarks of aging, including cataract formation, loss of motor coordination, decline in bone mineral density and increased aortic inelasticity (Baur et al., 2006; Pearson et al., 2008). Mitochondrial number declines in mice fed a high-calorie diet, and resveratrol treatment can reverse this decline. Consistent with its role as a SIRT1-activating compound, resveratrol reduces PGC-1 α acetylation levels, providing a potential mechanism for the increase in mitochondrial number (Baur et al., 2006). Treating mice with resveratrol activates PGC-1 α and induces genes involved in OXPHOS and mitochondrial biogenesis, resulting in increased mitochondrial size, number, and oxidative activity (Lagouge et al., 2006). Deletion of SIRT1 prevented similar effects in cell culture, arguing for a direct role for SIRT1 in regulation of mitochondrial number and oxidative capacity (Lagouge et al., 2006). Notably, microarray analyses revealed that both every other day feeding (a dietary regimen that produces lifespan extensions similar to CR) and resveratrol treatment produce significant upregulation of mitochondrial gene expression (Pearson et al., 2008). It is important to note that resveratrol can activate a variety of proteins, including AMPK, and this lack of specificity complicates interpretation of the above studies (Baur et al., 2006; Zang et al., 2006). Recently, SIRT1720 has been identified as a specific activator of SIRT1 (Milne et al., 2007; Feige et al., 2008). While SIRT1720 treatment results in PGC-1 α deacetylation and induction of genes involved in fatty acid oxidation, unlike resveratrol, SIRT1720 does not affect mitochondrial number (Feige et al., 2008). Thus, resveratrol's effects on mitochondrial density may stem from alternate targets, complex signaling networks, or dose-dependent interactions. In contrast, the ability of SIRT1 to cause a global shift towards fatty acid oxidation is supported by a number of pharmacologic and genetic models (Hallows et al., 2006; Feige et al., 2008; Rodgers et al., 2008).

An increasing body of evidence points to the beneficial impact of SIRT1 on age-related disease, particularly diabetes. Resveratrol treatment has been shown to increase insulin sensitivity and protect mice against diet-induced obesity and insulin resistance (Baur et al., 2006; Lagouge et al., 2006). SIRT1720 similarly lowers plasma glucose and improves insulin sensitivity in diet-induced and genetically obese mice (Milne et al., 2007). Moreover, SIRT1720 can improve glucose tolerance in chow fed mice, protect against diet-induced obesity and improve lipid and cholesterol profiles of mice on a high fat diet (Feige et al., 2008). Supporting the link between SIRT1 and insulin resistance, a study by Sun et al. (2007) found that experimentally inducing insulin resistance in cultured cells or in mice results in downregulation of SIRT1 expression. Importantly, knock-down of SIRT1 expression was sufficient to induce insulin resistance, and overexpression of SIRT1 under conditions of insulin resistance improved insulin sensitivity (Sun et al., 2007). The authors found that SIRT1 can repress expression of protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling, providing a potential mechanism for the effect of SIRT1 on insulin signaling in peripheral tissues (Sun et al., 2007). Furthermore, SIRT1 can regulate insulin secretion from pancreatic β cells, at least in part by regulating expression of uncoupling protein 2 (UCP2). Increased UCP2 expression reduces OXPHOS efficiency and ATP production, thus reducing insulin secretion, which is sensitive to the ATP/ADP ratio. Mice with β cell-specific

SIRT1 overexpression have reduced UCP2 levels and increased ATP production, enabling enhanced insulin secretion in response to glucose stimulation, although this effect is diminished when mice reach 18–24 months of age (Moynihan et al., 2005; Ramsey et al., 2008). Conversely, knock down of SIRT1 in β cell lines induces UCP2, lowers the ATP/ADP ratio and blunts insulin secretion, while SIRT1 null mice have constitutively elevated UCP2 expression and low levels of blood insulin (Bordone et al., 2006). The effects of SIRT1 on insulin secretion and glucose homeostasis are likely not limited to regulation of PTP1B and UCP2 expression, and it will be important for future studies to address how the effects of SIRT1 on other targets, including PGC-1 α , FOXO1 and NF- κ B, affect context-specific responses to insulin signaling.

SIRT1 protects against some models of neurodegeneration, although unlike CR, which convincingly delays neurodegeneration (Bruce-Keller et al., 1999; Duan et al., 2003; Maswood et al., 2004), the protective role of SIRT1 remains controversial. Although mitochondrial dysfunction plays an important role in many models of neurodegeneration, studies linking SIRT1 and neuronal survival have not addressed the potential for SIRT1 to ameliorate pathological changes in mitochondrial function. Because SIRT1 activates PGC-1 α , which can improve mitochondrial bioenergetics and resistance to oxidative damage, it will be important to investigate whether SIRT1 can mitigate neurodegeneration via PGC-1 α . Instead, many studies have implicated SIRT1 in stress response pathways: SIRT1 deacetylates p53 and represses its proapoptotic activity (Luo et al., 2001; Vaziri et al., 2001) and SIRT1 can deacetylate FOXO3, potentiating its ability to induce resistance to cell stress but inhibiting its ability to induce cell death (Brunet et al., 2004; Motta et al., 2004). In contrast, a recent study showed that SIRT1 inhibition increased neuronal resistance to oxidative damage and the brains of aged SIRT1-deficient mice displayed fewer markers of oxidative damage, suggesting that SIRT1 inhibition provides protection against oxidative stress *in vivo* (Li et al., 2008). Taken together, these studies suggest that SIRT1 may play diverse, context-specific roles in neuronal stress response pathways, and that careful investigation is needed to elucidate the conditions under which enhanced SIRT1 activity will be beneficial. Furthermore, while current studies emphasize targets such as p53, FOXO and NF- κ B as mediators of SIRT1-driven neuroprotection, it will be interesting to see if changes in mitochondrial number or bioenergetics play a role in the neuronal benefits of enhanced SIRT1 activity, given that defective mitochondrial bioenergetics are implicated in many neurodegenerative disorders (Wallace, 2005).

2.3. AMPK

Activity of the conserved AMP-activated protein kinase depends on the intracellular AMP/ATP ratio, enabling the kinase to serve as a sensor of cellular energy status. Stresses such as glucose deprivation, oxidative or hyperosmotic stress, ischemia, hypoxia and exercise deplete cellular ATP and increase AMPK activity (Kahn et al., 2005). AMPK activation triggers transcriptional and post-translational responses that coordinate appropriate changes in mitochondrial bioenergetics in order to respond to the stress of low energy (Nilsson et al., 2006; Osler and Zierath, 2008). For example, stimulation of AMPK activity induces transcription of PPAR α and PGC-1 α target genes, enabling a switch towards reliance on oxidation of fatty acids to replenish energy stores (Lee et al., 2006). Recently, AMPK has been shown to phosphorylate and activate transcriptional activity of FOXO3 (Greer et al., 2007a), and AMPK has been implicated in regulation of a wide variety of transcription factors, including HDAC5, p300, HNF4 α , TRIP6 and p53 (McGee and Hargreaves, 2008).

As a central regulator of pathways affected by aging and CR, including energy storage and oxidative metabolism, AMPK is

increasingly studied as a potential longevity regulator in model organisms (Table 1). In support of this hypothesis, two studies using independent models of CR in worms found that lifespan extension with dietary restriction requires the AMPK homolog *aak-2* (Greer et al., 2007b; Schulz et al., 2007). Similarly, overexpression of *aak-2* extends worm lifespan while worms with mutant *aak-2* have shortened lifespan (Apfeld et al., 2004). Interestingly, many common low-level stressors, such as high temperature pulse, cause an increase in the AMP/ATP ratio and result in lifespan extension, but the same treatment does not affect the lifespan of *aak-2* mutant worms (Apfeld et al., 2004). These studies suggest that increases in the AMP/ATP ratio may play an important role in the response to CR by signaling through *aak-2* to permit lifespan extension. In contrast, it appears that an increase in activity of Snf1p, the yeast homolog of AMPK, causes accelerated aging by increasing recombination at rDNA loci and encouraging the formation of extrachromosomal rDNA circles (ERC) (Ashrafi et al., 2000; Lin et al., 2003b). Notably, yeast Sir2 extends lifespan in yeast by suppressing ERC formation (Sinclair and Guarente, 1997; Kaeberlein et al., 1999). However, Snf1p is clearly necessary for the response to glucose restriction in yeast: in the absence of fermentable carbon sources, yeast derepress expression of genes involved in mitochondrial oxidative metabolism, and Snf1p is required for this metabolic switch (Hardie, 2004). Further study is necessary to resolve this apparent contradiction between the effect of AMPK homologs on lifespan in yeast and worms.

Given its ability to modulate mitochondrial number and substrate oxidation, mammalian AMPK is also a strong candidate for mediating mitochondrial changes during aging and CR. Nevertheless, two groups have shown that CR does not change AMPK activity in the heart or in skeletal muscle, and may even decrease AMPK activity in the liver (Gonzalez et al., 2004; To et al., 2007). On the other hand, AMPK activity does appear to change with age. One group found that the activity of AMPK decreases with age in rat skeletal muscle, and that this decline is associated with an increase in insulin resistance which can be blocked by treatment with AICAR, an AMP analog known to activate AMPK (Qiang et al., 2007). In contrast, Reznick et al. (2007) did not observe an age-related change in basal AMPK activity in mouse skeletal muscle, but they did find that stimuli such as AICAR, β -guanidinopropionic acid (β -GPA) feeding and exercise were able to increase AMPK activity in young, but not old, mice. Consequently, while β -GPA feeding resulted in a 38% increase in mitochondrial density in young mice, this effect was not seen in old mice, suggesting that impaired AMPK activation is linked to reduced mitochondrial biogenesis during aging (Reznick et al., 2007). It is unclear if these results can be generalized to tissues besides skeletal muscle, as one study showed that basal AMPK activity is increased in the liver of 24-month-old mice compared to 5-month-old mice, although this study also suggested that the responsiveness of AMPK activity declines with age (Mulligan et al., 2005). Interestingly, resveratrol activates AMPK as well as SIRT1, and it will be interesting to know whether AMPK contributes to the lifespan extension conferred by resveratrol treatment (Baur et al., 2006; Zang et al., 2006). More research is needed to determine how changes in AMPK activity may affect aging and if any of the benefits of CR are mediated by AMPK.

Growing evidence suggests that reductions in AMPK activity may be an important factor associated with the decreased mitochondrial biogenesis and fatty acid oxidation associated with aging. Certainly, modulations of AMPK activity can greatly influence these parameters. For example, several groups have found that pharmacological activation of AMPK through β -GPA or AICAR administration results in mitochondrial biogenesis in skeletal muscle, measured by increased NRF-1 binding activity and upregulation of key mitochondrial enzymes (Winder et al.,

2000; Bergeron et al., 2001). Importantly, β -GPA feeding did not affect mitochondrial number in mice expressing a dominant negative form of AMPK in skeletal muscle (Zong et al., 2002). Furthermore, a transgenic mouse overexpressing a gain-of-function mutant of the AMPK γ 3 subunit in skeletal muscle (γ 3^{225Q}) demonstrated elevated AMPK activity, resulting in increased expression of NRF-1, NRF-2, TFAM and PGC-1 α and increased mitochondrial biogenesis (Garcia-Roves et al., 2008).

Only recently have studies begun to shed light on the mechanism by which AMPK activity causes increased expression of transcriptional activators of mitochondrial biogenesis. Jager et al. (2007) showed that in cultured muscle cells, many of the transcriptional effects of AMPK activity, including the increase in expression of genes encoding mitochondrial proteins, require PGC-1 α . AMPK directly phosphorylates PGC-1 α , enhancing its activity at its own promoter and triggering a transcriptional cascade that increases expression of PGC-1 α and its target genes involved in mitochondrial biogenesis (Jager et al., 2007). PGC-1 α regulates expression of genes involved in fatty acid oxidation in skeletal muscle, and since AMPK can enhance PGC-1 α levels, it is not surprising that AMPK activation results in increased levels of enzymes required for fatty acid oxidation (Long et al., 2005). Accordingly, mice with the AMPK γ 3 subunit deleted in skeletal muscle have decreased expression of several genes involved in fatty acid oxidation, while (γ 3^{225Q}) mice have increased levels of these same genes (Nilsson et al., 2006).

Additionally, AMPK can regulate mitochondrial substrate oxidation at the post-translational level. AMPK phosphorylates and modulates the activity of a variety of metabolic proteins, including TSC2, PFK2, ACC1/2 and glycogen synthase, resulting in a general cellular switch away from biosynthesis towards ATP generating processes such as glucose uptake, glycolysis and fatty acid oxidation (Hardie, 2004). AMPK powerfully regulates mitochondrial fatty acid oxidation through phosphorylation of ACC1 and ACC2. As the rate-limiting enzyme in mitochondrial fatty acid uptake, carnitine palmitoyltransferase-1 (CPT1) is an important regulator of mitochondrial β -oxidation. CPT1, in turn, is allosterically inhibited by malonyl-CoA. ACC1/2 synthesize malonyl-CoA from acetyl-CoA, and it is thought that the malonyl-CoA generated by the cytoplasmic ACC1 is used for fatty acid synthesis, while the malonyl-CoA generated by the mitochondrially associated ACC2 is responsible for inhibition of mitochondrial fatty acid oxidation (Abu-Elheiga et al., 2001, 2005). Activated AMPK phosphorylates and inhibits both ACC1 and ACC2, simultaneously blocking fatty acid synthesis and activating mitochondrial fatty acid oxidation (Merrill et al., 1997; Vavvas et al., 1997; Hardie and Pan, 2002). Thus, during conditions of energy depletion, the switch from fatty acid synthesis to oxidation is mediated in a large part by the increased activity of AMPK. Although there is no evidence yet to suggest that mitochondrial changes that occur with aging or CR are mediated by AMPK, the fact that AMPK can positively influence many of the parameters that are negatively affected by aging makes it an important target for future study.

Increasingly, AMPK is viewed as a central player in mediating some of the beneficial effects of exercise and as a potential target for the treatment of diabetes. AMPK is activated by endurance training and pharmacological activation of AMPK by AICAR causes transcriptional changes similar to those seen during endurance exercise (Winder et al., 2006; Jorgensen and Rose, 2008). The importance of AMPK is controversial, as a dominant negative form of AMPK prevents the transcriptional changes induced by β -GPA, but exercise-induced increases in transcription are not blocked in mice lacking AMPK activity in skeletal muscle (Zong et al., 2002; Jorgensen et al., 2005). A recent study found that treating sedentary mice with AICAR alone was sufficient to induce genes involved in oxidative metabolism and to enhance running

endurance by 44% (Narkar et al., 2008). Similarly, increasing AMPK activity is believed to be a central mechanism for type 2 diabetes therapies (Hardie, 2008). In addition to its ability to increase mitochondrial number and fatty acid oxidation and to reduce fatty acid synthesis, AMPK can also stimulate GLUT4 translocation in skeletal muscle, thus increasing glucose uptake and metabolism. Since all of these processes are important parts of diabetes treatments, it is not surprising that many of the drugs used for type 2 diabetes, such as metformin and the thiazolidinediones, result in increased AMPK activity (Hardie, 2008). Genetic studies support the therapeutic potential of AMPK. For example, the ability of AICAR treatment to lower whole body glucose levels is abolished in mice lacking the catalytic α 2 subunit of AMPK, and γ 3^{225Q} mice are protected against diet-induced skeletal muscle insulin resistance (Mu et al., 2001; Barnes et al., 2004; Jorgensen et al., 2004; Long and Zierath, 2006). Clearly, AMPK has beneficial effects on pathways associated with aging and age-related disease and will continue to serve as an important therapeutic target in the treatment of metabolic diseases (McCarty, 2004).

2.4. mTOR

The conserved kinase target of rapamycin (TOR) integrates environmental cues to coordinate cell growth and metabolism (Wullschlegel et al., 2006; Cunningham et al., 2007). Recent studies have begun to explore the link between mTOR and mitochondrial energy production and have found that mTOR can increase both mitochondrial number and oxygen consumption. In mammals, mTOR exists in two distinct complexes, mTORC1 and mTORC2. mTORC1, including mTOR, RAPTOR, PRAS40 and mLST8, exerts effects on cell growth, protein synthesis and degradation, ribosome biogenesis and autophagy through targets including S6K1 and 4E-BP1 (Guertin and Sabatini, 2007). mTORC2 comprises mTOR, RICTOR, mSIN1, PROTOR and mLST8 and can affect growth, proliferation and survival, although to date, the only known target of mTORC2 is Akt (Guertin and Sabatini, 2007).

In model organisms, TOR has emerged as a powerful regulator of lifespan and the response to CR (Table 1). A large-scale screen for genes involved in yeast longevity yielded 10 hits, six of which correspond to components of the TOR and Sch9 (the yeast homolog of S6K1) pathways (Kaeberlein et al., 2005b). Deletion of TOR and Sch9 extends replicative lifespan, and CR does not further extend lifespan in these strains, suggesting that TOR and Sch9 are important effectors of the response to CR (Kaeberlein et al., 2005b). Additionally, both mutations in the conserved TOR pathway and pharmacological inhibition of TOR signaling increase yeast chronological life span (Powers et al., 2006; Wei et al., 2008). The pathway through which TOR exerts its effects on longevity in yeast are controversial: some reports suggest that it acts through Sir2 to stabilize rDNA, while others indicate that inhibition of protein synthesis is the primary factor driving lifespan extension (Medvedik et al., 2007; Steffen et al., 2008). Downregulation of TOR or components of TOR signaling similarly increase lifespan in worms and flies (Vellai et al., 2003; Jia et al., 2004; Kapahi et al., 2004; Honjoh et al., 2008). Several studies suggest that inhibition of protein synthesis extends lifespan in worms and flies, providing a potential mechanism for the increased longevity conferred by reduction of TOR signaling (Kapahi et al., 2004; Chen et al., 2007; Hansen et al., 2007; Pan et al., 2007; Steffen et al., 2008).

Because mTOR activity is suppressed by conditions of nutrient limitation, reduction in mTOR signaling is a logical candidate mechanism for the anti-aging benefits of CR. Nevertheless, it has proved extremely difficult to extend the results from model organisms to mammals, and there is surprisingly little evidence to link mTOR to aging or CR in mammals. One study found that mTOR signaling was reduced in the Ames Dwarf mouse, a model of

extended longevity, but few other studies provide direct links between mTOR signaling and mammalian aging (Sharp and Bartke, 2005). Unexpectedly, transcriptional profiling of heart and white adipose tissue from old mice revealed that aging reduced expression of genes associated with mTOR activity and that CR could block this reduction (Linford et al., 2007). Indeed, genetic models suggest that inhibition of mTOR activity has fatal consequences in mammals. Deletion of raptor, rictor, mLST8 or mTOR in mice results in embryonic lethality (Gangloff et al., 2004; Guertin et al., 2006; Shiota et al., 2006), and even skeletal muscle-specific deletion of raptor results in premature death between 4 and 7 months of age (Bentzinger et al., 2008). Intriguingly, these mice display reduced oxidative capacity and downregulated expression of PGC-1 α (Bentzinger et al., 2008).

Although mTORC1 is best known as a central controller of cell growth, recent studies have begun to uncover both direct and indirect roles for mTOR in the regulation of mitochondrial metabolism. Several studies associate downregulation of mTORC1 activity with increased fatty acid oxidation. Inhibition of mTORC1 by rapamycin reduces glycolysis and increases fatty acid oxidation in skeletal muscle cells and enables increased fatty acid oxidation coupled with reduced lipid synthesis in primary hepatocytes (Sipula et al., 2006; Brown et al., 2007). Compared to wild type counterparts, mice deficient for S6K1 have higher expression of genes involved in OXPHOS and fatty acid oxidation in both white adipose tissue and skeletal muscle (Um et al., 2004). Consistent with the hypothesis that these mice display elevated rates of fatty acid oxidation, S6K1^{-/-} mice have reduced fat stores and are protected from weight gain on a high fat diet (Um et al., 2004). Conversely, mice lacking 4E-BP1 and 4E-BP2, targets that are inhibited by mTORC1, show decreased lipolysis, increased fatty acid esterification and enhanced sensitivity to diet-induced obesity (Le Bacquer et al., 2007). All of these studies are consistent with the model that downregulation of mTORC1 activity and subsequent decrease in translation result in increased fatty acid catabolism.

mTORC1 can also enhance mitochondrial function independently of its regulation of protein translation. Schieke et al. (2006) first found that mTORC1 activity can stimulate mitochondrial oxygen consumption and oxidative capacity. Treating cells with rapamycin reduced $\Delta\psi_m$, oxygen consumption and maximum rate of OXPHOS independently of previously identified targets of mTORC1 (Schieke et al., 2006). The authors used 2D gel electrophoresis to examine mitochondrial proteins, and although they did not find changes in expression of proteins involved in OXPHOS or substrate oxidation, they did detect isoelectric shifts consistent with dephosphorylation of proteins involved in intermediate metabolism and OXPHOS (Schieke et al., 2006). Finally, two groups found that a fraction of mTOR physically localized with mitochondria, suggesting that mTOR can directly regulate mitochondrial metabolism (Desai et al., 2002; Schieke et al., 2006). An alternative model for regulation of mitochondrial activity by mTOR was provided by a recent study that showed that mTORC1 can positively influence transcription of genes important for mitochondrial biogenesis and substrate oxidation (Cunningham et al., 2007). Rapamycin treatment decreased transcription of genes controlling mitochondrial function, such as PGC-1 α , PGC-1 β , NRF-1 and ERR α . As a result, transcription of genes involved in OXPHOS declined, oxygen consumption fell and mitochondrial number was reduced with rapamycin treatment. Under normal conditions mTORC1 formed a complex with PGC-1 α and the transcription factor YY1 and this complex enabled transcription of nuclear-encoded mitochondrial genes. Upon rapamycin treatment, PGC-1 α broke away from the complex, and transcription of mitochondrial genes was downregulated (Cunningham et al., 2007). Both studies provide exciting evidence

that mTOR coordinates cell growth and mitochondrial metabolism. Clearly, future work is needed to elucidate the role of mTOR in regulating mitochondrial activity and to determine how such changes in mitochondrial respiration and substrate oxidation may be influenced by aging and CR.

3. Retrograde signaling

In order for nuclear proteins to regulate mitochondrial activity appropriately, mitochondria must be able to signal to the nucleus to alert the cell to changes in mitochondrial function. This retrograde (RTG) signaling enables the cell to adapt and compensate for perturbations in mitochondrial metabolism. Unlike anterograde transcriptional control of mitochondria, the retrograde response is not well studied and represents an important area of future research. Unicellular eukaryotes are capable of retrograde signaling and many of the genes involved have been identified in yeast. However, the molecular mechanisms driving retrograde signaling do not appear conserved across species (Liu and Butow, 2006).

3.1. Retrograde signaling in yeast

Disruption of energy production, whether by mutations in the TCA cycle or interruption of OXPHOS, trigger the retrograde response in yeast. In this event, the main function of the RTG pathways are the maintenance of glutamate supplies, which would otherwise be compromised as a result of blockage in the TCA cycle (Butow and Avadhani, 2004). The main RTG pathway in yeast relies on a family of Rtg proteins, of which Rtg2p senses mitochondrial dysfunction through an unknown mechanism. Under basal conditions, phosphorylation of Rtg3p sequesters both Rtg3p and Rtg1p in the cytoplasm. Upon mitochondrial dysfunction, activation of Rtg2p results in partial dephosphorylation of Rtg3p, with the result that Rtg3p and Rtg1p can translocate to the nucleus, where they heterodimerize to activate transcription of specific RTG target genes (Liu and Butow, 2006). Interestingly, TOR seems to play a regulatory role in the RTG pathway: rapamycin treatment results in upregulation of genes in the RTG pathway, and Lst8p, a component of TORC1 and TORC2, can negatively regulate RTG signaling (Liu and Butow, 2006). While the direct involvement of TOR is controversial, at least one study has found that TOR negatively regulates RTG signaling (Dilova et al., 2002). Furthermore, the retrograde response appears to play a direct role in the regulation of longevity in yeast. Growing yeast on medium containing raffinose will activate retrograde regulation and will also extend yeast replicative lifespan (Kirchman et al., 1999). The same study showed that yeast strains lacking mtDNA have increased longevity, and that deletion of a gene essential for RTG signaling eliminated the lifespan extension (Kirchman et al., 1999). The authors concluded that yeast lifespan extension, at least in response to mtDNA deletion, is proportional to the degree of RTG signaling (Kirchman et al., 1999). While the precise cues responsible for inducing the RTG pathway are unknown, it is clear that mitochondrial signaling may play an important role in yeast aging.

3.2. Retrograde signaling in mammals

Our understanding of mammalian retrograde signaling, also known as mitochondrial stress signaling, is much murkier. Mitochondria respond to accumulation of mutant or unfolded proteins with a mitochondrial unfolded protein response (UPR) analogous to the ER UPR. The mitochondrial UPR is regulated, at least in part, by the transcription factors CHOP and C/EBP β that increase expression of chaperones and proteases that are specific

to mitochondria, such as Hsp60, Hsp10 and ClpP (Zhao et al., 2002; Ryan and Hoogenraad, 2007). The specific signal that activates the mitochondrial UPR is still unknown, and it is unclear if this pathway is affected by aging or CR. Other forms of mitochondrial stress, such as perturbations in energy production or structural damage, signal to the nucleus through alternate mitochondrial stress response pathways (Ryan and Hoogenraad, 2007). These pathways are largely believed to be triggered by changes in mitochondrial release of metabolites and molecules, such as Ca^{2+} , nitric oxide (NO), ATP, NAD^+ / NADH and ROS (Fig. 1).

Mitochondria are important regulators of Ca^{2+} storage and homeostasis and cytosolic free Ca^{2+} ($[\text{Ca}^{2+}]_c$) is perhaps the best studied of the mammalian mitochondrial messengers. Mitochondrial membrane potential serves as a gauge of mitochondrial function: disruption of OXPHOS, interruption in the supply of nutrients or their catabolism and loss of mitochondrial structural integrity generally will result in a drop in $\Delta\psi_m$. A fall in $\Delta\psi_m$ disrupts mitochondrial Ca^{2+} uptake, producing a rise in $[\text{Ca}^{2+}]_c$ (Butow and Avadhani, 2004). As a result, depleting mitochondrial DNA with ethidium bromide or direct uncoupling with CCCP results in elevated cytosolic free Ca^{2+} and upregulation of genes involved in Ca^{2+} transport and storage (Luo et al., 1997; Biswas et al., 1999; Amuthan et al., 2002). Cybrid cells with mutant mitochondria or cells lacking mitochondrial DNA have elevated intracellular calcium, accompanied by activation of Ca^{2+} /calmodulin-dependent protein kinase (CaMK) (Arnould et al., 2002). Importantly, these studies showed that activation of Ca^{2+} -sensitive factors and subsequent changes in nuclear transcription were blocked by the removal of free Ca^{2+} with specific chelators (Butow and Avadhani, 2004). A rise in cytosolic free Ca^{2+} activates calcineurin and several Ca^{2+} -dependent kinases, such as PKC, CaMKIV, JNK and MAPK (Butow and Avadhani, 2004). Ultimately, Ca^{2+} signaling affects a wide variety of transcription factors, including NFAT, MEF2, TORC, CREB and NF- κ B, to produce appropriate cell-specific transcriptional responses (Mellstrom et al., 2008). Ca^{2+} signaling can in turn regulate mitochondrial function by activating PGC-1 α , providing an important regulatory loop for maintenance of mitochondrial activity. Mammalian cells treated with a chemical uncoupler suffer a temporary decline in ATP production but undergo an increase in transcription of mitochondrial genes and an increase in OXPHOS that serves to restore cellular ATP levels (Rohas et al., 2007). This compensatory response requires PGC-1 α and is mediated by Ca^{2+} -responsive CREB and TORCs associating at the PGC-1 α promoter, resulting in increased PGC-1 α transcription (Rohas et al., 2007). Similarly, overexpression of CaMKIV in skeletal muscle results in increased expression of PGC-1 α and enhanced mitochondrial biogenesis, OXPHOS and fatty acid oxidation (Wu et al., 2002).

Although cytosolic free Ca^{2+} is an important signal governing mitochondrial and cellular physiology, very few studies have investigated whether aging is associated with disruptions in Ca^{2+} homeostasis. There is scattered evidence to suggest that this is a promising area for future research. Calcineurin and CaMKIV activity decline with age in rat T cells, and CR diminishes the age-related decline in calcineurin activity (Pahlavani and Vargas, 1999, 2000). Suggestively, during aging in rats, several methionine residues of calmodulin are oxidized, disrupting normal interactions with target proteins (Anbanandam et al., 2005). The bulk of the research involving Ca^{2+} and aging has been carried out in neurons because of the critical role that Ca^{2+} plays in regulating neurotransmitter release, excitability and apoptosis, and subtle defects in Ca^{2+} homeostasis are implicated in neuronal aging and degeneration (Buchholz et al., 2007). While the values of resting intracellular Ca^{2+} do not appear to change with age, aging does slow the rate at which neurons can restore resting Ca^{2+} levels after large stimulation (Toescu, 2005). The role of mitochondria in

neuronal Ca^{2+} regulation during aging is controversial, but a number of studies suggest that the Ca^{2+} buffering capacity of mitochondria does not decrease with age and may even increase with age in order to compensate for reduced function of other Ca^{2+} -buffering systems (Buchholz et al., 2007). Increased Ca^{2+} uptake may place stress upon mitochondria and increase susceptibility to mitochondrially induced apoptosis (Buchholz et al., 2007). The intimate relationship between Ca^{2+} signaling, Ca^{2+} storage and mitochondrial function highlights this as an important area for future aging research.

Nitric oxide (NO) is synthesized from arginine and O_2 by NO synthase, of which there are several isoforms: endothelial (eNOS), neuronal (nNOS), inducible (iNOS) and mitochondrial (mtNOS) (Nisoli and Carruba, 2006). NO exerts systemic effects on energy metabolism by inducing vasodilation, thereby increasing nutrient supply, and by regulating the binding of O_2 to hemoglobin. NO can more directly influence mitochondrial energy production by competing with cytochrome c oxidase for O_2 , and this block in OXPHOS lowers O_2 consumption, $\Delta\psi_m$ and ATP production (Cleeter et al., 1994). Inhibition of cytochrome c oxidase by NO is highly sensitive to the rate of OXPHOS, suggesting that regulation by NO is coupled to the metabolic status of the cell (Brookes et al., 2002). As all isoforms of NOS require Ca^{2+} , an elegant feedback loop results whereby mitochondrial NO decreases $\Delta\psi_m$, which in turn reduces mitochondrial Ca^{2+} uptake and thus blocks mtNOS activity (Ghafourifar and Cadenas, 2005). Outside the mitochondria, NO plays an important role in mitochondrial biogenesis. NO synthesized by eNOS signals through cGMP to activate SIRT1 and PGC-1 α , resulting in an increase in mitochondrial number and oxidative capacity (Nisoli and Carruba, 2006). CR increases eNOS expression and cGMP production in various tissues, and deletion of eNOS abrogates increases in PGC-1 α expression and mitochondrial biogenesis typically induced by CR (Nisoli et al., 2005). While it is difficult to measure NO directly, indirect measures suggest that NO synthesis or secretion decline with age, and mtNOS activity is thought to decrease in the aging brain (Toprakci et al., 2000; Drew and Leeuwenburgh, 2002; Navarro and Boveris, 2008).

Mitochondrial NO can also signal to the nucleus by generating ROS. NO can combine with the superoxide radical to form peroxynitrite, a reactive radical capable of causing nitrosative damage to lipids, proteins and DNA (Drew and Leeuwenburgh, 2002). By blocking cytochrome c oxidase, NO can increase the reduction state of the electron transport chain, thus increasing the rate of electron leakage and superoxide production (Brookes et al., 2002). Given the damaging consequences of ROS activity, it is essential for cells to sense and respond to changes in ROS production. A variety of transcription factors are redox sensitive, including p53, AP-1, NF- κ B, Sp-1, glucocorticoid receptor and Egr-1 (Sun and Oberley, 1996). In most cases, oxidation or reduction of highly conserved cysteines in the DNA binding domain of the protein causes changes in transcriptional activity (Sun and Oberley, 1996). Additionally, oxidants can activate a variety of signaling pathways with diverse outcomes. Activation of ERK, PI3K/Akt and NF- κ B by oxidative stress triggers pro-survival pathways, while p53, JNK and p38 activation favor apoptosis, although there are numerous exceptions to this paradigm (Finkel and Holbrook, 2000).

Changes in redox state can directly affect pathways that control mitochondrial number and activity, providing an important feedback mechanism. Activity of NRF-1 and NRF-2 are modulated by changes in redox state. In the case of NRF-1, oxidants signal through the PI3K-Akt pathway to activate NRF-1 and induce transcription of mitochondrial genes (Martin et al., 1996; Suliman et al., 2003; Piantadosi and Suliman, 2006). Changes in redox state can also affect the stability of the mTOR complex, with oxidizing

agents increasing phosphorylation of S6K1 by mTOR (Sarbasov and Sabatini, 2005). Alterations in mitochondrial ROS production have profound and varied effects on cell signaling in order to tailor changes in cellular and mitochondrial activity appropriately. Because mitochondrial ROS production increases with age, changes in redox signaling pathways can have important consequences during aging. Indeed, enhanced stress resistance is linked to extended life span in worms, flies and mice (Finkel and Holbrook, 2000).

ATP is another mitochondrial product with potent signaling capacities. Mitochondrial ATP is exchanged for cytosolic ADP through the mitochondrial adenine nucleotide transporter (ANT), and a rise in mitochondrial ATP production will increase the cytosolic ATP/ADP ratio. This change will reduce AMPK activity and relieve the repression of anabolic processes. Additionally, AMPK can regulate mTOR at several levels: AMPK phosphorylates and activates the mTOR repressor TSC2 and AMPK can phosphorylate raptor to inhibit mTORC1 directly (Inoki et al., 2003; Shaw et al., 2004; Gwinn et al., 2008). An increase in the ATP/ADP ratio will therefore increase mTOR activity, and there is some evidence that ATP can directly stimulate mTOR kinase activity as well (Dennis et al., 2001). Conversely, a variety of stresses that disrupt mitochondrial OXPHOS inhibit mTOR kinase activity (Kim et al., 2002). Thus, ATP can serve as an important signal to coordinate cell growth and proliferation with mitochondrial energy production. Determining whether basal ATP levels or the rate of ATP production change during aging has proved very controversial. Many studies have examined activity of specific complexes of the respiratory chain in an effort to understand how mitochondrial OXPHOS capacity varies with age. Respiratory complexes do not respond to aging uniformly and there is no common pattern between various tissues (Yen et al., 1989; Kwong and Sohal, 2000). Physical fitness, activity and body fat are potentially confounding variables that render analysis of mitochondrial OXPHOS activity especially contentious in skeletal muscle, and different studies report either no change or a decline in mitochondrial respiratory capacity during aging (Cooper et al., 1992; Chretien et al., 1998; Conley et al., 2000; Petersen et al., 2003; Rasmussen et al., 2003; Tonkonogi et al., 2003; Lanza et al., 2005). Direct measures of ATP production and content in the heart, brain and skeletal muscle showed that ATP content and production declined with age only in skeletal muscle, and that CR did not affect these parameters in any of the tissues studied (Drew and Leeuwenburgh, 2003; Drew et al., 2003). It will be important for future studies to address not only how ATP levels change with age, but also whether aging is associated with alterations in the ATP/ADP ratios and in the sensitivity of cellular signaling pathways to perturbations in the ratio.

NAD⁺ and NADH are crucial metabolites intimately connected with mitochondrial energy production that can also affect mitochondrial function by regulating the mitochondrial permeability transition pore, voltage-dependent anion channels and calcium homeostasis (Ying, 2006). Changes in the cellular NAD⁺/NADH ratio can change the redox state of the cell and alter the activity of enzymes such as poly-ADP-ribose polymerases and sirtuins, with subsequent effects on signaling cascades and gene expression (Rodgers et al., 2005; Ying, 2006). The NAD⁺/NADH ratio changes in a tissue-specific pattern during CR and has been linked to aging in yeast (Lin et al., 2004b; Chen et al., 2008). However, it is unclear if changes in the mitochondrial NAD⁺/NADH ratio can have any effect on the cytosolic NAD⁺/NADH ratio. The inner mitochondrial membrane is impermeable to NAD⁺ and NADH, enabling the mitochondrial NAD⁺:NADH ratio to fall between 7 and 8:1 while the cytosolic NAD⁺/NADH ratio is approximately 700:1 (Ying, 2006). Indeed, this is the basis for the “mitochondrial oasis theory” proposed by Yang et al. (2007), which

suggests that cells can survive the depletion of cytosolic NAD⁺ that occurs following genotoxic stress because mitochondrial NAD⁺ levels are preserved. However, the mitochondrial malate–aspartate shuttle provides a mechanism whereby cytosolic NADH can transfer reducing equivalents to mitochondrial NAD⁺, generating mitochondrial NADH, and there is some evidence that changes in the mitochondrial energy state can modify the extramitochondrial redox state (Bremer and Davis, 1975). Overexpressing components of the malate–aspartate shuttle in yeast extends lifespan and deleting the shuttle components blocks both the increase in lifespan and decrease in cytosolic NADH characteristic of CR (Easlon et al., 2008). It is possible, therefore, that under certain conditions, changes in mitochondrial energy state can be translated into subtle differences in the cytosolic NAD⁺/NADH ratio, with consequences for aging and longevity. A NAD⁺-carrier protein was recently discovered in yeast, raising the intriguing possibility that such a shuttle may exist in mammals and provide a more direct mechanism for mitochondria to influence the cytosolic NAD⁺/NADH ratio (Todisco et al., 2006).

4. Perspectives and future directions

Communication between the mitochondria and nucleus is crucial for maintenance of appropriate mitochondrial function. As a result, mitochondrial-nuclear signaling plays an integral role in normal energy homeostasis and disruption contributes to aging and age-related disease. Elucidating the molecular mechanisms that regulate these pathways will be essential for understanding the dysregulation of mitochondrial function that is associated with aging. Recent studies have begun to uncover the complex integration of the various signaling pathways that coordinate to regulate mitochondrial gene expression (Fig. 1). While the major players regulating transcription of mitochondrial genes, namely PGC-1 α , SIRT1, AMPK and mTOR, have begun to be studied in great detail, the signals through which mitochondria communicate to the nucleus are largely unknown. Although Ca²⁺, NO, ATP/ADP, ROS and NAD⁺/NADH are suspected to be important interorganelle messengers, mammalian retrograde signaling remains a major unexplored avenue for aging research. It will be important for future studies to investigate how aging affects the signals that mitochondria emit in addition to the responsiveness of downstream signaling pathways. A better understanding of this bidirectional communication will enable a new avenue of therapies that improve nuclear-mitochondrial communication. Finally, a new generation of therapeutics such as AICAR, resveratrol and SRT1720 demonstrate the promise of targeting pathways involved in the cross-talk between the nucleus and mitochondria.

Acknowledgements

We thank Zoltan Arany, John T. Cunningham, Vincent de Boer and Brian North for comments on the manuscript. L.F. is supported by a National Science Foundation graduate student research fellowship. M.H. is supported by grants from The Brookdale Foundation, The Glenn Foundation for Medical Research, and The Giovanni Armenise-Harvard Foundation.

References

- Abu-Elheiga, L., Matzuk, M.M., Abo-Hashema, K.A., Wakil, S.J., 2001. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. *Science* 291, 2613–2616.
- Abu-Elheiga, L., Matzuk, M.M., Kordari, P., Oh, W., Shaikenov, T., Gu, Z., Wakil, S.J., 2005. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. *Proc. Natl. Acad. Sci. U.S.A.* 102, 12011–12016.
- Abu-Ereish, G.M., Neely, J.R., Whitmer, J.T., Whitman, V., Sanadi, D.R., 1977. Fatty acid oxidation by isolated perfused working hearts of aged rats. *Am. J. Physiol.* 232, E258–262.

- Al-Regaiey, K.A., Masternak, M.M., Bonkowski, M., Sun, L., Bartke, A., 2005. Long-lived growth hormone receptor knockout mice: interaction of reduced insulin-like growth factor I/insulin signaling and caloric restriction. *Endocrinology* 146, 851–860.
- Allard, J.S., Heilbronn, L.K., Smith, C., Hunt, N.D., Ingram, D.K., Ravussin, E., de Cabo, R., 2008. In vitro cellular adaptations of indicators of longevity in response to treatment with serum collected from humans on calorie restricted diets. *PLoS ONE* 3, e3211.
- Amuthan, G., Biswas, G., Anandatheerthavarada, H.K., Vijayarathy, C., Shephard, H.M., Avadhani, N.G., 2002. Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. *Oncogene* 21, 7839–7849.
- Anbanandam, A., Bieber Urbauer, R.J., Bartlett, R.K., Smallwood, H.S., Squier, T.C., Urbauer, J.L., 2005. Mediating molecular recognition by methionine oxidation: conformational switching by oxidation of methionine in the carboxyl-terminal domain of calmodulin. *Biochemistry* 44, 9486–9496.
- Anderson, R.M., Barger, J.L., Edwards, M.G., Braun, K.H., O'Connor, C.E., Prolla, T.A., Weindruch, R., 2008. Dynamic regulation of PGC-1 α localization and turnover implicates mitochondrial adaptation in calorie restriction and the stress response. *Aging Cell* 7, 101–111.
- Apfeld, J., O'Connor, G., McDonagh, T., DiStefano, P.S., Curtis, R., 2004. The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in *C. elegans*. *Genes Dev.* 18, 3004–3009.
- Arany, Z., Lebrasseur, N., Morris, C., Smith, E., Yang, W., Ma, Y., Chin, S., Spiegelman, B.M., 2007. The transcriptional coactivator PGC-1 β drives the formation of oxidative type IIX fibers in skeletal muscle. *Cell Metabol.* 5, 35–46.
- Arany, Z., He, H., Lin, J., Hoyer, K., Handschin, C., Toka, O., Ahmad, F., Matsui, T., Chin, S., Wu, P.H., Rybkin, I.L., Shelton, J.M., Manieri, M., Cinti, S., Schoen, F.J., Bassel-Duby, R., Rosenzweig, A., Ingwall, J.S., Spiegelman, B.M., 2005. Transcriptional coactivator PGC-1 α controls the energy state and contractile function of cardiac muscle. *Cell Metabol.* 1, 259–271.
- Arnould, T., Vankoningsloo, S., Renard, P., Houbion, A., Ninane, N., Demazy, C., Remacle, J., Raes, M., 2002. CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell proliferation. *EMBO J.* 21, 53–63.
- Ashrafi, K., Lin, S.S., Manchester, J.K., Gordon, J.I., 2000. Sip2p and its partner snf1p kinase affect aging in *S. cerevisiae*. *Genes Dev.* 14, 1872–1885.
- Baar, K., Wendt, A.R., Jones, T.E., Marison, M., Nolte, L.A., Chen, M., Kelly, D.P., Holloszy, J.O., 2002. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. *FASEB J.* 16, 1879–1886.
- Baker, D.J., Betik, A.C., Krause, D.J., Hepple, R.T., 2006. No decline in skeletal muscle oxidative capacity with aging in long-term calorically restricted rats: effects are independent of mitochondrial DNA integrity. *J. Gerontol. A Biol. Sci. Med. Sci.* 61, 675–684.
- Banks, A.S., Kon, N., Knight, C., Matsumoto, M., Gutierrez-Juarez, R., Rossetti, L., Gu, W., Accili, D., 2008. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. *Cell Metabol.* 8, 333–341.
- Barger, J.L., Kayo, T., Vann, J.M., Arias, E.B., Wang, J., Hacker, T.A., Wang, Y., Raederstorff, D., Morrow, J.D., Leeuwenburgh, C., Allison, D.B., Saupe, K.W., Carter, G.D., Weindruch, R., Prolla, T.A., 2008. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. *PLoS ONE* 3, e2264.
- Barnes, B.R., Marklund, S., Steiler, T.L., Walter, M., Hjalml, G., Amarger, V., Mahlapuu, M., Leng, Y., Johansson, C., Galuska, D., Lindgren, K., Abrink, M., Stapleton, D., Zierath, J.R., Andersson, L., 2004. The 5'-AMP-activated protein kinase gamma3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. *J. Biol. Chem.* 279, 38441–38447.
- Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K., Pistell, P.J., Poosala, S., Becker, K.G., Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K.W., Spencer, R.G., Lakatta, E.G., Le Couteur, D., Shaw, R.J., Navas, P., Puigserver, P., Ingram, D.K., de Cabo, R., Sinclair, D.A., 2006. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 444, 337–342.
- Bentzinger, C.F., Romanino, K., Cloetta, D., Lin, S., Mascarenhas, J.B., Oliveri, F., Xia, J., Casanova, E., Costa, C.F., Brink, M., Zorzato, F., Hall, M.N., Rugg, M.A., 2008. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. *Cell Metabol.* 8, 411–424.
- Bergeron, R., Ren, J.M., Cadman, K.S., Moore, I.K., Perret, P., Pypaert, M., Young, L.H., Semenkovich, C.F., Shulman, G.I., 2001. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. *Am. J. Physiol. Endocrinol. Metabol.* 281, E1340–1346.
- Bevilacqua, L., Ramsey, J.J., Hagopian, K., Weindruch, R., Harper, M.E., 2004. Effects of short- and medium-term calorie restriction on muscle mitochondrial proton leak and reactive oxygen species production. *Am. J. Physiol. Endocrinol. Metabol.* 286, E852–861.
- Bevilacqua, L., Ramsey, J.J., Hagopian, K., Weindruch, R., Harper, M.E., 2005. Long-term caloric restriction increases UCP3 content but decreases proton leak and reactive oxygen species production in rat skeletal muscle mitochondria. *Am. J. Physiol. Endocrinol. Metabol.* 289, E429–438.
- Bishop, N.A., Guarente, L., 2007. Two neurons mediate diet-restriction-induced longevity in *C. elegans*. *Nature* 447, 545–549.
- Biswas, G., Adebajo, O.A., Freedman, B.D., Anandatheerthavarada, H.K., Vijayarathy, C., Zaidi, M., Kotlikoff, M., Avadhani, N.G., 1999. Retrograde Ca²⁺ signaling in C₂C₁₂ skeletal myocytes in response to mitochondrial genetic and metabolic stress: a novel mode of inter-organellar crosstalk. *EMBO J.* 18, 522–533.
- Bluhner, M., Kahn, B.B., Kahn, C.R., 2003. Extended longevity in mice lacking the insulin receptor in adipose tissue. *Science* 299, 572–574.
- Boily, G., Seifert, E.L., Bevilacqua, L., He, X.H., Sabourin, G., Estey, C., Moffat, C., Crawford, S., Saliba, S., Jardine, K., Xuan, J., Evans, M., Harper, M.E., McBurney, M.W., 2008. SirT1 regulates energy metabolism and response to caloric restriction in mice. *PLoS ONE* 3, e1759.
- Bordone, L., Guarente, L., 2005. Calorie restriction. SIRT1 and metabolism: understanding longevity. *Nat. Rev. Mol. Cell. Biol.* 6, 298–305.
- Bordone, L., Cohen, D., Robinson, A., Motta, M.C., van Veen, E., Czopik, A., Steele, A.D., Crowe, H., Marmor, S., Luo, J., Gu, W., Guarente, L., 2007. SIRT1 transgenic mice show phenotypes resembling calorie restriction. *Aging Cell* 6, 759–767.
- Bordone, L., Motta, M.C., Picard, F., Robinson, A., Jhala, U.S., Apfeld, J., McDonagh, T., Lemieux, M., McBurney, M., Szilvasi, A., Easlon, E.J., Lin, S.J., Guarente, L., 2006. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. *PLoS Biol.* 4, e31.
- Bremer, J., Davis, E.J., 1975. Studies on the active transfer of reducing equivalents into mitochondria via the malate-aspartate shuttle. *Biochim. Biophys. Acta* 376, 387–397.
- Brookes, P.S., Levenon, A.L., Shiva, S., Sarti, P., Darley-Usmar, V.M., 2002. Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen species. *Free Radic. Biol. Med.* 33, 755–764.
- Brown, N.F., Stefanovic-Racic, M., Sipula, I.J., Perdomo, G., 2007. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. *Metabolism* 56, 1500–1507.
- Bruce-Keller, A.J., Umberger, G., McFall, R., Mattson, M.P., 1999. Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. *Ann. Neurol.* 45, 8–15.
- Brunet, A., Sweeney, L.B., Sturgill, J.F., Chua, K.F., Greer, P.L., Lin, Y., Tran, H., Ross, S.E., Mostoslavsky, R., Cohen, H.Y., Hu, L.S., Cheng, H.L., Jedrychowski, M.P., Gygi, S.P., Sinclair, D.A., Alt, F.W., Greenberg, M.E., 2004. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. *Science* 303, 2011–2015.
- Buchholz, J.N., Behringer, E.J., Pottorf, W.J., Pearce, W.J., Vanterpool, C.K., 2007. Age-dependent changes in Ca²⁺ homeostasis in peripheral neurons: implications for changes in function. *Aging Cell* 6, 285–296.
- Butow, R.A., Avadhani, N.G., 2004. Mitochondrial signaling: the retrograde response. *Mol. Cell* 14, 1–15.
- Calvo, J.A., Daniels, T.G., Wang, X., Paul, A., Lin, J., Spiegelman, B.M., Stevenson, S.C., Rangwala, S.M., 2008. Muscle-specific expression of PPARgamma coactivator-1alpha improves exercise performance and increases peak oxygen uptake. *J. Appl. Physiol.* 104, 1304–1312.
- Cartwright, M.J., Tchkonja, T., Kirkland, J.L., 2007. Aging in adipocytes: potential impact of inherent, depot-specific mechanisms. *Exp. Gerontol.* 42, 463–471.
- Chen, D., Steele, A.D., Lindquist, S., Guarente, L., 2005. Increase in activity during calorie restriction requires Sirt1. *Science* 310, 1641.
- Chen, D., Pan, K.Z., Palter, J.E., Kapahi, P., 2007. Longevity determined by developmental arrest genes in *Caenorhabditis elegans*. *Aging Cell* 6, 525–533.
- Chen, D., Bruno, J., Easlon, E., Lin, S.J., Cheng, H.L., Alt, F.W., Guarente, L., 2008. Tissue-specific regulation of SIRT1 by calorie restriction. *Genes Dev.* 22, 1753–1757.
- Choi, C.S., Befroy, D.E., Codella, R., Kim, S., Reznick, R.M., Hwang, Y.J., Liu, Z.X., Lee, H.Y., DiStefano, A., Samuel, V.T., Zhang, D., Cline, G.W., Handschin, C., Lin, J., Petersen, K.F., Spiegelman, B.M., Shulman, G.I., 2008. Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. *Proc. Natl. Acad. Sci. U.S.A.* 105, 19926–19931.
- Chretien, D., Gallego, J., Barrientos, A., Casademont, J., Cardellach, F., Munnich, A., Rotig, A., Rustin, P., 1998. Biochemical parameters for the diagnosis of mitochondrial respiratory chain deficiency in humans, and their lack of age-related changes. *Biochem. J.* 329 (Pt 2), 249–254.
- Civitaresse, A.E., Carling, S., Heilbronn, L.K., Hulver, M.H., Ukropcova, B., Deutsch, W.A., Smith, S.R., Ravussin, E., 2007. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. *PLoS Med.* 4, e76.
- Cleeter, M.W., Cooper, J.M., Darley-Usmar, V.M., Moncada, S., Schapira, A.H., 1994. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. *FEBS Lett.* 345, 50–54.
- Cohen, H.Y., Miller, C., Bitterman, K.J., Wall, N.R., Hekking, B., Kessler, B., Howitz, K.T., Gorospe, M., de Cabo, R., Sinclair, D.A., 2004. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. *Science* 305, 390–392.
- Comfort, A., 1963. Effect of delayed and resumed growth on the longevity of a fish (*Lebistes Reticulatus*, Peters) in captivity. *Gerontologia* 49, 150–155.
- Conley, K.E., Jubrias, S.A., Esselman, P.C., 2000. Oxidative capacity and ageing in human muscle. *J. Physiol.* 526 (Pt 1), 203–210.
- Conley, K.E., Jubrias, S.A., Amara, C.E., Marcinek, D.J., 2007. Mitochondrial dysfunction: impact on exercise performance and cellular aging. *Exerc. Sport Sci. Rev.* 35, 43–49.
- Cooper, J.M., Mann, V.M., Schapira, A.H., 1992. Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of ageing. *J. Neurol. Sci.* 113, 91–98.
- Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N., Krainc, D., 2006. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. *Cell* 127, 59–69.
- Cunningham, J.T., Rodgers, J.T., Arlow, D.H., Vazquez, F., Mootha, V.K., Puigserver, P., 2007. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. *Nature* 450, 736–740.
- Dennis, P.B., Jaeschke, A., Saitoh, M., Fowler, B., Kozma, S.C., Thomas, G., 2001. Mammalian TOR: a homeostatic ATP sensor. *Science* 294, 1102–1105.

- Desai, B.N., Myers, B.R., Schreiber, S.L., 2002. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. *Proc. Natl. Acad. Sci. U.S.A.* 99, 4319–4324.
- Dilova, I., Chen, C.Y., Powers, T., 2002. Mks1 in concert with TOR signaling negatively regulates RTG target gene expression in *S. cerevisiae*. *Curr. Biol.* 12, 389–395.
- Drew, B., Leeuwenburgh, C., 2002. Aging and the role of reactive nitrogen species. *Ann. N. Y. Acad. Sci.* 959, 66–81.
- Drew, B., Leeuwenburgh, C., 2003. Method for measuring ATP production in isolated mitochondria: ATP production in brain and liver mitochondria of Fischer-344 rats with age and caloric restriction. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 285, R1259–1267.
- Drew, B., Phaneuf, S., Dirks, A., Selman, C., Gredilla, R., Lezza, A., Barja, G., Leeuwenburgh, C., 2003. Effects of aging and caloric restriction on mitochondrial energy production in gastrocnemius muscle and heart. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 284, R474–480.
- Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.J., Mattson, M.P., 2003. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. *Proc. Natl. Acad. Sci. U.S.A.* 100, 2911–2916.
- Easlon, E., Tsang, F., Skinner, C., Wang, C., Lin, S.J., 2008. The malate-aspartate NADH shuttle components are novel metabolic longevity regulators required for calorie restriction-mediated life span extension in yeast. *Genes Dev.* 22, 931–944.
- Easlon, E., Tsang, F., Dilova, I., Wang, C., Lu, S.P., Skinner, C., Lin, S.J., 2007. The dihydrolipoamide acetyltransferase is a novel metabolic longevity factor and is required for calorie restriction-mediated life span extension. *J. Biol. Chem.* 282, 6161–6171.
- Feige, J.N., Lagouge, M., Canto, C., Strehle, A., Houten, S.M., Milne, J.C., Lambert, P.D., Matak, C., Elliott, P.J., Auwerx, J., 2008. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. *Cell Metabol.* 8, 347–358.
- Finck, B.N., Kelly, D.P., 2006. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. *J. Clin. Invest.* 116, 615–622.
- Finkel, T., Holbrook, N.J., 2000. Oxidants, oxidative stress and the biology of ageing. *Nature* 408, 239–247.
- Frye, R.A., 2000. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. *Biochem. Biophys. Res. Commun.* 273, 793–798.
- Gangloff, Y.G., Mueller, M., Dann, S.G., Svoboda, P., Sticker, M., Spetz, J.F., Um, S.H., Brown, E.J., Cereghini, S., Thomas, G., Kozma, S.C., 2004. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. *Mol. Cell. Biol.* 24, 9508–9516.
- Garcia-Roves, P.M., Osler, M.E., Holmstrom, M.H., Zierath, J.R., 2008. Gain-of-function R225Q mutation in AMP-activated protein kinase gamma 3 subunit increases mitochondrial biogenesis in glycolytic skeletal muscle. *J. Biol. Chem.*
- Gerhart-Hines, Z., Rodgers, J.T., Bare, O., Lerin, C., Kim, S.H., Mostoslavsky, R., Alt, F.W., Wu, Z., Puigserver, P., 2007. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. *EMBO J.* 26, 1913–1923.
- Ghafourifar, P., Cadenas, E., 2005. Mitochondrial nitric oxide synthase. *Trends Pharmacol. Sci.* 26, 190–195.
- Gleyzer, N., Vercauteren, K., Scarpulla, R.C., 2005. Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. *Mol. Cell. Biol.* 25, 1354–1366.
- Goffart, S., Wiesner, R.J., 2003. Regulation and co-ordination of nuclear gene expression during mitochondrial biogenesis. *Exp. Physiol.* 88, 33–40.
- Gonzalez, A.A., Kumar, R., Mulligan, J.D., Davis, A.J., Weindruch, R., Saupe, K.W., 2004. Metabolic adaptations to fasting and chronic caloric restriction in heart, muscle, and liver do not include changes in AMPK activity. *Am. J. Physiol. Endocrinol. Metab.* 287, E1032–1037.
- Goto, M., Terada, S., Kato, M., Katoh, M., Yokozeki, T., Tabata, I., Shimokawa, T., 2000. cDNA cloning and mRNA analysis of PGC-1 in epitrochlearis muscle in swimming-exercised rats. *Biochem. Biophys. Res. Commun.* 274, 350–354.
- Gredilla, R., Sanz, A., Lopez-Torres, M., Barja, G., 2001. Caloric restriction decreases mitochondrial free radical generation at complex I and lowers oxidative damage to mitochondrial DNA in the rat heart. *FASEB J.* 15, 1589–1591.
- Greer, E.L., Oskoui, P.R., Banko, M.R., Maniar, J.M., Gygi, M.P., Gygi, S.P., Brunet, A., 2007a. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. *J. Biol. Chem.* 282, 30107–30119.
- Greer, E.L., Dowlatshahi, D., Banko, M.R., Villen, J., Hoang, K., Blanchard, D., Gygi, S.P., Brunet, A., 2007b. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in *C. elegans*. *Curr. Biol.* 17, 1646–1656.
- Guarente, L., 2006. Sirtuins as potential targets for metabolic syndrome. *Nature* 444, 868–874.
- Guertin, D.A., Sabatini, D.M., 2007. Defining the role of mTOR in cancer. *Cancer Cell* 12, 9–22.
- Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., Moffat, J., Brown, M., Fitzgerald, K.J., Sabatini, D.M., 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. *Dev. Cell* 11, 859–871.
- Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., Turk, B.E., Shaw, R.J., 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol. Cell* 30, 214–226.
- Hagen, T.M., Yowe, D.L., Bartholomew, J.C., Wehr, C.M., Do, K.L., Park, J.Y., Ames, B.N., 1997. Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase. *Proc. Natl. Acad. Sci. U.S.A.* 94, 3064–3069.
- Haigis, M.C., Guarente, L.P., 2006. Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction. *Genes Dev.* 20, 2913–2921.
- Hallows, W.C., Lee, S., Denu, J.M., 2006. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. *Proc. Natl. Acad. Sci. U.S.A.* 103, 10230–10235.
- Handschin, C., Spiegelman, B.M., 2006. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. *Endocr. Rev.* 27, 728–735.
- Handschin, C., Choi, C.S., Chin, S., Kim, S., Kawamori, D., Kurpad, A.J., Neubauer, N., Hu, J., Mootha, V.K., Kim, Y.B., Kulkarni, R.N., Shulman, G.I., Spiegelman, B.M., 2007. Abnormal glucose homeostasis in skeletal muscle-specific PGC-1alpha knockout mice reveals skeletal muscle-pancreatic beta cell crosstalk. *J. Clin. Invest.* 117, 3463–3474.
- Hansen, M., Taubert, S., Crawford, D., Libina, N., Lee, S.J., Kenyon, C., 2007. Lifespan extension by conditions that inhibit translation in *Caenorhabditis elegans*. *Ageing Cell* 6, 95–110.
- Hardie, D.G., 2004. The AMP-activated protein kinase pathway—new players upstream and downstream. *J. Cell. Sci.* 117, 5479–5487.
- Hardie, D.G., 2008. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. *FEBS Lett.* 582, 81–89.
- Hardie, D.G., Pan, D.A., 2002. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. *Biochem. Soc. Trans.* 30, 1064–1070.
- Harman, D., 1956. Aging: a theory based on free radical and radiation chemistry. *J. Gerontol.* 11, 298–300.
- Hepple, R.T., Baker, D.J., McConkey, M., Muryinka, T., Norris, R., 2006. Caloric restriction protects mitochondrial function with aging in skeletal and cardiac muscles. *Rejuvenation Res.* 9, 219–222.
- Holloszy, J.O., Booth, F.W., 1976. Biochemical adaptations to endurance exercise in muscle. *Annu. Rev. Physiol.* 38, 273–291.
- Honjoh, S., Yamamoto, T., Uno, M., Nishida, E., 2008. Signalling through RHEB-1 mediates intermittent fasting-induced longevity in *C. elegans*. *Nature*.
- Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G., Zipkin, R.E., Chung, P., Kisielewski, A., Zhang, L.L., Scherer, B., Sinclair, D.A., 2003. Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* 425, 191–196.
- Hunt, N.D., Hyun, D.H., Allard, J.S., Minor, R.K., Mattson, M.P., Ingram, D.K., de Cabo, R., 2006. Bioenergetics of aging and calorie restriction. *Ageing Res. Rev.* 5, 125–143.
- Huss, J.M., Kelly, D.P., 2004. Nuclear receptor signaling and cardiac energetics. *Circ. Res.* 95, 568–578.
- Huss, J.M., Kelly, D.P., 2005. Mitochondrial energy metabolism in heart failure: a question of balance. *J. Clin. Invest.* 115, 547–555.
- Inoki, K., Zhu, T., Guan, K.L., 2003. TSC2 mediates cellular energy response to control cell growth and survival. *Cell* 115, 577–590.
- Jager, S., Handschin, C., St-Pierre, J., Spiegelman, B.M., 2007. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. *Proc. Natl. Acad. Sci. U.S.A.* 104, 12017–12022.
- Jia, K., Chen, D., Riddle, D.L., 2004. The TOR pathway interacts with the insulin signaling pathway to regulate *C. elegans* larval development, metabolism and life span. *Development* 131, 3897–3906.
- Johnson, D.T., Harris, R.A., French, S., Blair, P.V., You, J., Bemis, K.G., Wang, M., Balaban, R.S., 2007. Tissue heterogeneity of the mammalian mitochondrial proteome. *Am. J. Physiol. Cell. Physiol.* 292, C689–C697.
- Jorgensen, S.B., Rose, A.J., 2008. How is AMPK activity regulated in skeletal muscles during exercise? *Front Biosci.* 13, 5589–5604.
- Jorgensen, S.B., Viollet, B., Andreelli, F., Froisig, C., Birk, J.B., Schjerling, P., Vaulont, S., Richter, E.A., Wojtaszewski, J.F., 2004. Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside but not contraction-induced glucose uptake in skeletal muscle. *J. Biol. Chem.* 279, 1070–1079.
- Jorgensen, S.B., Wojtaszewski, J.F., Viollet, B., Andreelli, F., Birk, J.B., Hellsten, Y., Schjerling, P., Vaulont, S., Neuffer, P.D., Richter, E.A., Pilegaard, H., 2005. Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. *FASEB J.* 19, 1146–1148.
- Jubrias, S.A., Esselman, P.C., Price, L.B., Cress, M.E., Conley, K.E., 2001. Large energetic adaptations of elderly muscle to resistance and endurance training. *J. Appl. Physiol.* 90, 1663–1670.
- Kaeberlein, M., McVey, M., Guarente, L., 1999. The SIR2/3/4 complex and SIR2 alone promote longevity in *Saccharomyces cerevisiae* by two different mechanisms. *Genes Dev.* 13, 2570–2580.
- Kaeberlein, M., Hu, D., Kerr, E.O., Tsuchiya, M., Westman, E.A., Dang, N., Fields, S., Kennedy, B.K., 2005a. Increased life span due to calorie restriction in respiratory-deficient yeast. *PLoS Genet.* 1, e69.
- Kaeberlein, M., Powers 3rd, R.W., Steffen, K.K., Westman, E.A., Hu, D., Dang, N., Kerr, E.O., Kirkland, K.T., Fields, S., Kennedy, B.K., 2005b. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. *Science* 310, 1193–1196.
- Kahn, B.B., Alquier, T., Carling, D., Hardie, D.G., 2005. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metabol.* 1, 15–25.
- Kapahi, P., Zid, B.M., Harper, T., Koslover, D., Sapin, V., Benzer, S., 2004. Regulation of lifespan in *Drosophila* by modulation of genes in the TOR signaling pathway. *Curr. Biol.* 14, 885–890.
- Katic, M., Kennedy, A.R., Leykin, I., Norris, A., McGettrick, A., Gesta, S., Russell, S.J., Blüher, M., Maratos-Flier, E., Kahn, C.R., 2007. Mitochondrial gene expression and increased oxidative metabolism: role in increased lifespan of fat-specific insulin receptor knock-out mice. *Ageing Cell* 6, 827–839.

- Kelly, D.P., Scarpulla, R.C., 2004. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. *Genes Dev.* 18, 357–368.
- Kim, D.H., Sarbassov, D.D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-Bromage, H., Tempst, P., Sabatini, D.M., 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell* 110, 163–175.
- Kirchman, P.A., Kim, S., Lai, C.Y., Jazwinski, S.M., 1999. Interorganelle signaling is a determinant of longevity in *Saccharomyces cerevisiae*. *Genetics* 152, 179–190.
- Kwong, L.K., Sohal, R.S., 2000. Age-related changes in activities of mitochondrial electron transport complexes in various tissues of the mouse. *Arch. Biochem. Biophys.* 373, 16–22.
- Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P., Auwerx, J., 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 α . *Cell* 127, 1109–1122.
- Lambert, A.J., Wang, B., Yardley, J., Edwards, J., Merry, B.J., 2004. The effect of aging and caloric restriction on mitochondrial protein density and oxygen consumption. *Exp. Gerontol.* 39, 289–295.
- Lanza, I.R., Befroy, D.E., Kent-Braun, J.A., 2005. Age-related changes in ATP-producing pathways in human skeletal muscle in vivo. *J. Appl. Physiol.* 99, 1736–1744.
- Le Bacquer, O., Petroulakis, E., Paglialunga, S., Poulin, F., Richard, D., Cianflone, C., Sonenberg, N., 2007. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. *J. Clin. Invest.* 117, 387–396.
- Lee, C.K., Allison, D.B., Brand, J., Weindruch, R., Prolla, T.A., 2002. Transcriptional profiles associated with aging and middle age-onset caloric restriction in mouse hearts. *Proc. Natl. Acad. Sci. U.S.A.* 99, 14988–14993.
- Lee, S.S., Lee, R.Y., Fraser, A.G., Kamath, R.S., Ahringer, J., Ruvkun, G., 2003. A systematic RNAi screen identifies a critical role for mitochondria in *C. elegans* longevity. *Nat. Genet.* 33, 40–48.
- Lee, W.J., Kim, M., Park, H.S., Kim, H.S., Jeon, M.J., Oh, K.S., Koh, E.H., Won, J.C., Kim, M.S., Oh, G.T., Yoon, M., Lee, K.U., Park, J.Y., 2006. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPAR α and PGC-1. *Biochem. Biophys. Res. Commun.* 340, 291–295.
- Lehman, J.J., Barger, P.M., Kovacs, A., Saffitz, J.E., Medeiros, D.M., Kelly, D.P., 2000. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. *J. Clin. Invest.* 106, 847–856.
- Leone, T.C., Lehman, J.J., Finck, B.N., Schaeffer, P.J., Wende, A.R., Boudina, S., Courtois, M., Wozniak, D.F., Sambandam, N., Bernal-Mizrachi, C., Chen, Z., Holloszy, J.O., Medeiros, D.M., Schmidt, R.E., Saffitz, J.E., Abel, E.D., Semenkovich, C.F., Kelly, D.P., 2005. PGC-1 α deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. *PLoS Biol.* 3, e101.
- Li, Y., Xu, W., McBurney, M.W., Longo, V.D., 2008. SirT1 inhibition reduces IGF-1/IRS-2/Ras/ERK1/2 signaling and protects neurons. *Cell Metabol.* 8, 38–48.
- Lin, J., Tarr, P.T., Yang, R., Rhee, J., Puigserver, P., Newgard, C.B., Spiegelman, B.M., 2003a. PGC-1 β in the regulation of hepatic glucose and energy metabolism. *J. Biol. Chem.* 278, 30843–30848.
- Lin, J., Wu, H., Tarr, P.T., Zhang, C.Y., Wu, Z., Boss, O., Michael, L.F., Puigserver, P., Isotani, E., Olson, E.N., Lowell, B.B., Bassel-Duby, R., Spiegelman, B.M., 2002a. Transcriptional co-activator PGC-1 α drives the formation of slow-twitch muscle fibres. *Nature* 418, 797–801.
- Lin, J., Wu, P.H., Tarr, P.T., Lindenberg, K.S., St-Pierre, J., Zhang, C.Y., Mootha, V.K., Jager, S., Vianna, C.R., Reznick, R.M., Cui, L., Manieri, M., Donovan, M.X., Wu, Z., Cooper, M.P., Fan, M.C., Rohas, L.M., Zavacki, A.M., Cinti, S., Shulman, G.I., Lowell, B.B., Krauss, D., Spiegelman, B.M., 2004a. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1 α null mice. *Cell* 119, 121–135.
- Lin, S.J., Defossez, P.A., Guarente, L., 2000. Requirement of NAD and SIR2 for life-span extension by caloric restriction in *Saccharomyces cerevisiae*. *Science* 289, 2126–2128.
- Lin, S.J., Ford, E., Haigis, M., Liszt, G., Guarente, L., 2004b. Calorie restriction extends yeast life span by lowering the level of NADH. *Genes Dev.* 18, 12–16.
- Lin, S.J., Kaeberlein, M., Andalis, A.A., Sturtz, L.A., Defossez, P.A., Culotta, V.C., Fink, G.R., Guarente, L., 2002b. Calorie restriction extends *Saccharomyces cerevisiae* lifespan by increasing respiration. *Nature* 418, 344–348.
- Lin, S.S., Manchester, J.K., Gordon, J.I., 2003b. Sip2, an N-myristoylated beta subunit of Snf1 kinase, regulates aging in *Saccharomyces cerevisiae* by affecting cellular histone kinase activity, recombination at rDNA loci, and silencing. *J. Biol. Chem.* 278, 13390–13397.
- Linford, N.J., Beyer, R.P., Gollahon, K., Krajcik, R.A., Malloy, V.L., Demas, V., Burmer, G.C., Rabinovitch, P.S., 2007. Transcriptional response to aging and caloric restriction in heart and adipose tissue. *Ageing Cell* 6, 673–688.
- Ling, C., Poulsen, P., Carlsson, E., Ridderstrale, M., Almgren, P., Wojtaszewski, J., Beck-Nielsen, H., Groop, L., Vaag, A., 2004. Multiple environmental and genetic factors influence skeletal muscle PGC-1 α and PGC-1 β gene expression in twins. *J. Clin. Invest.* 114, 1518–1526.
- Liu, Z., Butow, R.A., 2006. Mitochondrial retrograde signaling. *Annu. Rev. Genet.* 40, 159–185.
- Loeb, J., Northrop, J.H., 1917. On the influence of food and temperature upon the duration of life. *J. Biol. Chem.* 32, 103–121.
- Long, Y.C., Zierath, J.R., 2006. AMP-activated protein kinase signaling in metabolic regulation. *J. Clin. Invest.* 116, 1776–1783.
- Long, Y.C., Barnes, B.R., Mahlapuu, M., Steiler, T.L., Martinsson, S., Leng, Y., Wallberg-Henriksson, H., Andersson, L., Zierath, J.R., 2005. Role of AMP-activated protein kinase in the coordinated expression of genes controlling glucose and lipid metabolism in mouse white skeletal muscle. *Diabetologia* 48, 2354–2364.
- Lopez-Lluch, G., Hunt, N., Jones, B., Zhu, M., Jamieson, H., Hilmer, S., Cascajo, M.V., Allard, J., Ingram, D.K., Navas, P., de Cabo, R., 2006. Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency. *Proc. Natl. Acad. Sci. U.S.A.* 103, 1768–1773.
- Lowell, B.B., Shulman, G.I., 2005. Mitochondrial dysfunction and type 2 diabetes. *Science* 307, 384–387.
- Lu, T., Pan, Y., Kao, S.Y., Li, C., Kohane, I., Chan, J., Yankner, B.A., 2004. Gene regulation and DNA damage in the ageing human brain. *Nature* 429, 883–891.
- Luo, J., Nikolaev, A.Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., Gu, W., 2001. Negative control of p53 by Sir2 α promotes cell survival under stress. *Cell* 107, 137–148.
- Luo, Y., Bond, J.D., Ingram, V.M., 1997. Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases. *Proc. Natl. Acad. Sci. U.S.A.* 94, 9705–9710.
- Martin, M.E., Chinenov, Y., Yu, M., Schmidt, T.K., Yang, X.Y., 1996. Redox regulation of GA-binding protein- α DNA binding activity. *J. Biol. Chem.* 271, 25617–25623.
- Maswood, N., Young, J., Tilmont, E., Zhang, Z., Gash, D.M., Gerhardt, G.A., Grondin, R., Roth, G.S., Mattison, J., Lane, M.A., Carson, R.E., Cohen, R.M., Mouton, P.R., Quigley, C., Mattson, M.P., Ingram, D.K., 2004. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. *Proc. Natl. Acad. Sci. U.S.A.* 101, 18171–18176.
- McCarty, M.F., 2004. Chronic activation of AMP-activated kinase as a strategy for slowing aging. *Med. Hypotheses* 63, 334–339.
- McCay, C.M., Crowell, M.F., Maynard, L.A., 1989. The effect of retarded growth upon the length of life span and upon the ultimate body size. 1935. *Nutrition* 5, 155–171 discussion 172.
- McGee, S.L., Hargreaves, M., 2008. AMPK and transcriptional regulation. *Front Biosci.* 13, 3022–3033.
- Medvedik, O., Lammung, D.W., Kim, K.D., Sinclair, D.A., 2007. MSN2 and MSN4 link calorie restriction and TOR to sirtuin-mediated lifespan extension in *Saccharomyces cerevisiae*. *PLoS Biol.* 5, e261.
- Melanson, K.J., Saltzman, E., Russell, R.R., Roberts, S.B., 1997. Fat oxidation in response to four graded energy challenges in younger and older women. *Am. J. Clin. Nutr.* 66, 860–866.
- Mellstrom, B., Savignac, M., Gomez-Villafuertes, R., Naranjo, J.R., 2008. Ca²⁺-operated transcriptional networks: molecular mechanisms and in vivo models. *Physiol. Rev.* 88, 421–449.
- Melov, S., Tarnopolsky, M.A., Beckman, K., Felkey, K., Hubbard, A., 2007. Resistance exercise reverses aging in human skeletal muscle. *PLoS ONE* 2, e465.
- Menshikova, E.V., Ritov, V.B., Fairfull, L., Ferrell, R.E., Kelley, D.E., Goodpaster, B.H., 2006. Effects of exercise on mitochondrial content and function in aging human skeletal muscle. *J. Gerontol. A Biol. Sci. Med. Sci.* 61, 534–540.
- Merrill, G.F., Kurth, E.J., Hardie, D.G., Winder, W.W., 1997. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. *Am. J. Physiol.* 273, E1107–1112.
- Merry, B.J., 2002. Molecular mechanisms linking calorie restriction and longevity. *Int. J. Biochem. Cell. Biol.* 34, 1340–1354.
- Merry, B.J., 2004. Oxidative stress and mitochondrial function with aging—the effects of calorie restriction. *Ageing Cell* 3, 7–12.
- Michishita, E., Park, J.Y., Burneskis, J.M., Barrett, J.C., Horikawa, I., 2005. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. *Mol. Biol. Cell.* 16, 4623–4635.
- Milne, J.C., Lambert, P.D., Schenk, S., Carney, D.P., Smith, J.J., Gagne, D.J., Jin, L., Boss, O., Perni, R.B., Vu, C.B., Bemis, J.E., Xie, R., Disch, J.S., Ng, P.Y., Nunes, J.J., Lynch, A.V., Yang, H., Galonek, H., Israelian, K., Choy, W., Iffland, A., Lavu, S., Medvedik, O., Sinclair, D.A., Olefsky, J.M., Jirousek, M.R., Elliott, P.J., Westphal, C.H., 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. *Nature* 450, 712–716.
- Miwa, S., Lawless, C., von Zglinicki, T., 2008. Mitochondrial turnover in liver is fast in vivo and is accelerated by dietary restriction: application of a simple dynamic model. *Ageing Cell* 7, 920–923.
- Mootha, V.K., Handschin, C., Arlow, D., Xie, X., St Pierre, J., Sihag, S., Yang, W., Altshuler, D., Puigserver, P., Patterson, N., Willy, P.J., Schulman, I.G., Heyman, R.A., Lander, E.S., Spiegelman, B.M., 2004. Erralpha and Galpha/b specify PGC-1 α -dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. *Proc. Natl. Acad. Sci. U.S.A.* 101, 6570–6575.
- Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., Houstis, N., Daly, M.J., Patterson, N., Mesirov, J.P., Golub, T.R., Tamayo, P., Spiegelman, B., Lander, E.S., Hirschhorn, J.N., Altshuler, D., Groop, L.C., 2003. PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* 34, 267–273.
- Morino, K., Petersen, K.F., Befroy, D., Frattini, J., Shatzkes, N., Neschen, S., White, M.F., Bilz, S., Sono, S., Pypaert, M., Shulman, G.I., 2005. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. *J. Clin. Invest.* 115, 3587–3593.
- Motta, M.C., Divecha, N., Lemieux, M., Kamel, C., Chen, D., Gu, W., Bultsma, Y., McBurney, M., Guarente, L., 2004. Mammalian SIRT1 represses forkhead transcription factors. *Cell* 116, 551–563.
- Moyinhan, K.A., Grimm, A.A., Plueger, M.M., Bernal-Mizrachi, E., Ford, E., Cras-Meneur, C., Permut, M.A., Imai, S., 2005. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. *Cell Metabol.* 2, 105–117.

- Mu, J., Brozinick Jr., J.T., Valladares, O., Bucan, M., Birnbaum, M.J., 2001. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. *Mol. Cell* 7, 1085–1094.
- Mulligan, J.D., Gonzalez, A.A., Kumar, R., Davis, A.J., Saupe, K.W., 2005. Aging elevates basal adenosine monophosphate-activated protein kinase (AMPK) activity and eliminates hypoxic activation of AMPK in mouse liver. *J. Gerontol. A Biol. Sci. Med. Sci.* 60, 21–27.
- Nakamura, Y., Ogura, M., Tanaka, D., Inagaki, N., 2008. Localization of mouse mitochondrial SIRT proteins: shift of SIRT3 to nucleus by co-expression with SIRT5. *Biochem. Biophys. Res. Commun.* 366, 174–179.
- Narkar, V.A., Downes, M., Yu, R.T., Embler, E., Wang, Y.X., Banayo, E., Mihaylova, M.M., Nelson, M.C., Zou, Y., Juguilon, H., Kang, H., Shaw, R.J., Evans, R.M., 2008. AMPK and PPARdelta agonists are exercise mimetics. *Cell* 134, 405–415.
- Navarro, A., Boveris, A., 2007. The mitochondrial energy transduction system and the aging process. *Am. J. Physiol. Cell. Physiol.* 292, C670–686.
- Navarro, A., Boveris, A., 2008. Mitochondrial nitric oxide synthase, mitochondrial brain dysfunction in aging, and mitochondria-targeted antioxidants. *Adv. Drug Deliv. Rev.* 60, 1534–1544.
- Nilsson, E.C., Long, Y.C., Martinsson, S., Glund, S., Garcia-Roves, P., Svensson, L.T., Andersson, L., Zierath, J.R., Mahlapuu, M., 2006. Opposite transcriptional regulation in skeletal muscle of AMP-activated protein kinase gamma3 R225Q transgenic versus knock-out mice. *J. Biol. Chem.* 281, 7244–7252.
- Nisoli, E., Carruba, M.O., 2006. Nitric oxide and mitochondrial biogenesis. *J. Cell. Sci.* 119, 2855–2862.
- Nisoli, E., Tonello, C., Cardile, A., Cozzi, V., Bracale, R., Tedesco, L., Falcone, S., Valerio, A., Cantoni, O., Clementi, E., Moncada, S., Carruba, M.O., 2005. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. *Science* 310, 314–317.
- North, B.J., Verdin, E., 2007. Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. *PLoS ONE* 2, e784.
- Oberdoerffer, P., Michan, S., McVay, M., Mostoslavsky, R., Vann, J., Park, S.K., Hartlerode, A., Stegmuller, J., Hafner, A., Loerch, P., Wright, S.M., Mills, K.D., Bonni, A., Yankner, B.A., Scully, R., Prolla, T.A., Alt, F.W., Sinclair, D.A., 2008. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. *Cell* 135, 907–918.
- Osler, M.E., Zierath, J.R., 2008. Adenosine 5'-monophosphate-activated protein kinase regulation of fatty acid oxidation in skeletal muscle. *Endocrinology* 149, 935–941.
- Pagliarini, D.J., Calvo, S.E., Chang, B., Sheth, S.A., Vafai, S.B., Ong, S.E., Walford, G.A., Sugiana, C., Boneh, A., Chen, W.K., Hill, D.E., Vidal, M., Evans, J.G., Thorburn, D.R., Carr, S.A., Mootha, V.K., 2008. A mitochondrial protein compendium elucidates complex I disease biology. *Cell* 134, 112–123.
- Pahlavani, M.A., Vargas, D.M., 1999. Age-related decline in activation of calcium/calmodulin-dependent phosphatase calcineurin and kinase CaMK-IV in rat T cells. *Mech. Ageing Dev.* 112, 59–74.
- Pahlavani, M.A., Vargas, D.M., 2000. Influence of aging and caloric restriction on activation of Ras/MAPK, calcineurin, and CaMK-IV activities in rat T cells. *Proc. Soc. Exp. Biol. Med.* 223, 163–169.
- Pan, K.Z., Palter, J.E., Rogers, A.N., Olsen, A., Chen, D., Lithgow, G.J., Kapahi, P., 2007. Inhibition of mRNA translation extends lifespan in *Caenorhabditis elegans*. *Ageing Cell* 6, 111–119.
- Park, S.Y., Kim, Y.W., Kim, J.E., Kim, J.Y., 2006. Age-associated changes in fat metabolism in the rat and its relation to sympathetic activity. *Life Sci.* 79, 2228–2233.
- Patti, M.E., Butte, A.J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., Kohane, I., Costello, M., Saccone, R., Landaker, E.J., Goldfine, A.B., Mun, E., DeFronzo, R., Finlayson, J., Kahn, C.R., Mandarino, L.J., 2003. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. *Proc. Natl. Acad. Sci. U.S.A.* 100, 8466–8471.
- Pearson, K.J., Baur, J.A., Lewis, K.N., Peshkin, L., Price, N.L., Labinskyy, N., Swindell, W.R., Kamara, D., Minor, R.K., Perez, E., Jamieson, H.A., Zhang, Y., Dunn, S.R., Sharma, K., Pleshko, N., Woollett, L.A., Csiszar, A., Ikeno, Y., Le Couteur, D., Elliott, P.J., Becker, K.G., Navas, P., Ingram, D.K., Wolf, N.S., Ungvari, Z., Sinclair, D.A., de Cabo, R., 2008. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. *Cell Metabol.* 8, 157–168.
- Petersen, K.F., Dufour, S., Befroy, D., Garcia, R., Shulman, G.I., 2004. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. *N. Engl. J. Med.* 350, 664–671.
- Petersen, K.F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D.L., DiPietro, L., Cline, G.W., Shulman, G.I., 2003. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. *Science* 300, 1140–1142.
- Piantadosi, C.A., Suliman, H.B., 2006. Mitochondrial transcription factor A induction by redox activation of nuclear respiratory factor 1. *J. Biol. Chem.* 281, 324–333.
- Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., Leid, M., McBurney, M.W., Guarente, L., 2004. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. *Nature* 429, 771–776.
- Pilegaard, H., Saltin, B., Neuffer, P.D., 2003. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. *J. Physiol.* 546, 851–858.
- Powers 3rd, R.W., Kaeblerlein, M., Caldwell, S.D., Kennedy, B.K., Fields, S., 2006. Extension of chronological life span in yeast by decreased TOR pathway signaling. *Genes Dev.* 20, 174–184.
- Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M., Spiegelman, B.M., 1998. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* 92, 829–839.
- Qiang, W., Weiqiang, K., Qing, Z., Pengju, Z., Yi, L., 2007. Aging impairs insulin-stimulated glucose uptake in rat skeletal muscle via suppressing AMPKalpha. *Exp. Mol. Med.* 39, 535–543.
- Ramsey, K.M., Mills, K.F., Satoh, A., Imai, S., 2008. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. *Ageing Cell* 7, 78–88.
- Rasmussen, U.F., Krstrup, P., Kjaer, M., Rasmussen, H.N., 2003. Human skeletal muscle mitochondrial metabolism in youth and senescence: no signs of functional changes in ATP formation and mitochondrial oxidative capacity. *Pflügers Arch.* 446, 270–278.
- Reznick, R.M., Zong, H., Li, J., Morino, K., Moore, I.K., Yu, H.J., Liu, Z.X., Dong, J., Mustard, K.J., Hawley, S.A., Befroy, D., Pypaert, M., Hardie, D.G., Young, L.H., Shulman, G.I., 2007. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. *Cell Metabol.* 5, 151–156.
- Rodgers, J.T., Lerin, C., Gerhart-Hines, Z., Puigserver, P., 2008. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. *FEBS Lett.* 582, 46–53.
- Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., Puigserver, P., 2005. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. *Nature* 434, 113–118.
- Rogina, B., Helfand, S.L., 2004. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. *Proc. Natl. Acad. Sci. U.S.A.* 101, 15998–16003.
- Rohas, L.M., St-Pierre, J., Uldry, M., Jager, S., Handschin, C., Spiegelman, B.M., 2007. A fundamental system of cellular energy homeostasis regulated by PGC-1alpha. *Proc. Natl. Acad. Sci. U.S.A.* 104, 7933–7938.
- Russell, A.P., Feilchenfeldt, J., Schreiber, S., Praz, M., Crettenand, A., Gobelet, C., Meier, C.A., Bell, D.R., Kralli, A., Giacobino, J.P., Deriaz, O., 2003. Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. *Diabetes* 52, 2874–2881.
- Russell, L.K., Mansfield, C.M., Lehman, J.J., Kovacs, A., Courtois, M., Saffitz, J.E., Medeiros, D.M., Valencik, M.L., McDonald, J.A., Kelly, D.P., 2004. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. *Circ. Res.* 94, 525–533.
- Ryan, M.T., Hoogenraad, N.J., 2007. Mitochondrial-nuclear communications. *Annu. Rev. Biochem.* 76, 701–722.
- Sanz, A., Caro, P., Ibanez, J., Gomez, J., Gredilla, R., Barja, G., 2005. Dietary restriction at old age lowers mitochondrial oxygen radical production and leak at complex I and oxidative DNA damage in rat brain. *J. Bioenergy Biomembr.* 37, 83–90.
- Sarbasov, D.D., Sabatini, D.M., 2005. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. *J. Biol. Chem.* 280, 39505–39509.
- Sasaki, T., Maier, B., Bartke, A., Scoble, H., 2006. Progressive loss of SIRT1 with cell cycle withdrawal. *Ageing Cell* 5, 413–422.
- Sastre, J., Pallardo, F.V., Pla, R., Pellin, A., Juan, G., O'Connor, J.E., Estrela, J.M., Miquel, J., Vina, J., 1996. Aging of the liver: age-associated mitochondrial damage in intact hepatocytes. *Hepatology* 24, 1199–1205.
- Scarpulla, R.C., 2002. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. *Biochim. Biophys. Acta* 1576, 1–14.
- Scarpulla, R.C., 2008. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. *Physiol. Rev.* 88, 611–638.
- Scher, M.B., Vaquero, A., Reinberg, D., 2007. SirT3 is a nuclear NAD+ -dependent histone deacetylase that translocates to the mitochondria upon cellular stress. *Genes Dev.* 21, 920–928.
- Schieke, S.M., Phillips, D., McCoy Jr., J.P., Aponte, A.M., Shen, R.F., Balaban, R.S., Finkel, T., 2006. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. *J. Biol. Chem.* 281, 27643–27652.
- Schon, E.A., Manfredi, G., 2003. Neuronal degeneration and mitochondrial dysfunction. *J. Clin. Invest.* 111, 303–312.
- Schulz, T.J., Zarse, K., Voigt, A., Urban, N., Birringer, M., Ristow, M., 2007. Glucose restriction extends *Caenorhabditis elegans* life span by inducing mitochondrial respiration and increasing oxidative stress. *Cell Metabol.* 6, 280–293.
- Schwer, B., Verdin, E., 2008. Conserved metabolic regulatory functions of sirtuins. *Cell Metabol.* 7, 104–112.
- Sharp, Z.D., Bartke, A., 2005. Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. *J. Gerontol. A Biol. Sci. Med. Sci.* 60, 293–300.
- Shaw, R.J., Bardeesy, N., Manning, B.D., Lopez, L., Kosmatka, M., DePinho, R.A., Cantley, L.C., 2004. The LKB1 tumor suppressor negatively regulates mTOR signaling. *Cancer Cell* 6, 91–99.
- Shi, T., Wang, F., Stieren, E., Tong, Q., 2005. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. *J. Biol. Chem.* 280, 13560–13567.
- Shiota, C., Woo, J.T., Lindner, J., Shelton, K.D., Magnuson, M.A., 2006. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. *Dev. Cell* 11, 583–589.
- Short, K.R., Vittone, J.L., Bigelow, M.L., Proctor, D.N., Rizza, R.A., Coenen-Schimke, J.M., Nair, K.S., 2003. Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity. *Diabetes* 52, 1888–1896.

- Short, K.R., Bigelow, M.L., Kahl, J., Singh, R., Coenen-Schimke, J., Raghavakaimal, S., Nair, K.S., 2005. Decline in skeletal muscle mitochondrial function with aging in humans. *Proc. Natl. Acad. Sci. U.S.A.* 102, 5618–5623.
- Sinclair, D.A., Guarente, L., 1997. Extrachromosomal rDNA circles—a cause of aging in yeast. *Cell* 91, 1033–1042.
- Sipula, I.J., Brown, N.F., Perdomo, G., 2006. Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. *Metabolism* 55, 1637–1644.
- Sohal, R.S., Weindruch, R., 1996. Oxidative stress, caloric restriction, and aging. *Science* 273, 59–63.
- Sohal, R.S., Ku, H.H., Agarwal, S., Forster, M.J., Lal, H., 1994. Oxidative damage, mitochondrial oxidant generation and antioxidant defenses during aging and in response to food restriction in the mouse. *Mech. Ageing Dev.* 74, 121–133.
- Solomon, T.P., Marchetti, C.M., Krishnan, R.K., Gonzalez, F., Kirwan, J.P., 2008. Effects of aging on basal fat oxidation in obese humans. *Metabolism* 57, 1141–1147.
- St-Pierre, J., Lin, J., Krauss, S., Tarr, P.T., Yang, R., Newgard, C.B., Spiegelman, B.M., 2003. Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. *J. Biol. Chem.* 278, 26597–26603.
- St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jager, S., Handschin, C., Zheng, K., Lin, J., Yang, W., Simon, D.K., Bachoo, R., Spiegelman, B.M., 2006. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. *Cell* 127, 397–408.
- Steffen, K.K., MacKay, V.L., Kerr, E.O., Tsuchiya, M., Hu, D., Fox, L.A., Dang, N., Johnston, E.D., Oakes, J.A., Tchao, B.N., Pak, D.N., Fields, S., Kennedy, B.K., Kaeblerlein, M., 2008. Yeast life span extension by depletion of 60 s ribosomal subunits is mediated by Gcn4. *Cell* 133, 292–302.
- Suliman, H.B., Carraway, M.S., Welty-Wolf, K.E., Whorton, A.R., Piantadosi, C.A., 2003. Lipopolysaccharide stimulates mitochondrial biogenesis via activation of nuclear respiratory factor-1. *J. Biol. Chem.* 278, 41510–41518.
- Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X., Zhai, Q., 2007. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. *Cell Metabol.* 6, 307–319.
- Sun, Y., Oberley, L.W., 1996. Redox regulation of transcriptional activators. *Free Radic. Biol. Med.* 21, 335–348.
- Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K., Horio, Y., 2007. Nucleocytoplasmic shuttling of the NAD⁺-dependent histone deacetylase SIRT1. *J. Biol. Chem.* 282, 6823–6832.
- Terada, S., Kawanaka, K., Goto, M., Shimokawa, T., Tabata, I., 2005. Effects of high-intensity intermittent swimming on PGC-1alpha protein expression in rat skeletal muscle. *Acta Physiol. Scand.* 184, 59–65.
- Terman, A., 2006. Catabolic insufficiency and aging. *Ann. N. Y. Acad. Sci.* 1067, 27–36.
- Tissenbaum, H.A., Guarente, L., 2001. Increased dosage of a sir-2 gene extends lifespan in *Caenorhabditis elegans*. *Nature* 410, 227–230.
- To, K., Yamaza, H., Komatsu, T., Hayashida, T., Hayashi, H., Toyama, H., Chiba, T., Higami, Y., Shimokawa, I., 2007. Down-regulation of AMP-activated protein kinase by calorie restriction in rat liver. *Exp. Gerontol.* 42, 1063–1071.
- Todisco, S., Agrimi, G., Castegna, A., Palmieri, F., 2006. Identification of the mitochondrial NAD⁺ transporter in *Saccharomyces cerevisiae*. *J. Biol. Chem.* 281, 1524–1531.
- Toescu, E.C., 2005. Normal brain ageing: models and mechanisms. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 360, 2347–2354.
- Tonkonogi, M., Fernstrom, M., Walsh, B., Ji, L.L., Rooyackers, O., Hammarqvist, F., Wernerman, J., Sahlin, K., 2003. Reduced oxidative power but unchanged antioxidative capacity in skeletal muscle from aged humans. *Pflugers Arch.* 446, 261–269.
- Toprakci, M., Ozmen, D., Mutaf, I., Turgan, N., Parildar, Z., Habif, S., Guner, I., Bayindir, O., 2000. Age-associated changes in nitric oxide metabolites nitrite and nitrate. *Int. J. Clin. Lab Res.* 30, 83–85.
- Tucker, M.Z., Turcotte, L.P., 2002. Impaired fatty acid oxidation in muscle of aging rats perfused under basal conditions. *Am. J. Physiol. Endocrinol. Metabol.* 282, E1102–1109.
- Um, S.H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P.R., Kozma, S.C., Auwerx, J., Thomas, G., 2004. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature* 431, 200–205.
- Vavvas, D., Apazidis, A., Saha, A.K., Gamble, J., Patel, A., Kemp, B.E., Witters, L.A., Ruderman, N.B., 1997. Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle. *J. Biol. Chem.* 272, 13255–13261.
- Vaziri, H., Dessain, S.K., Ng Eaton, E., Imai, S.I., Frye, R.A., Pandita, T.K., Guarente, L., Weinberg, R.A., 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. *Cell* 107, 149–159.
- Vellai, T., Takacs-Vellai, K., Zhang, Y., Kovacs, A.L., Orosz, L., Muller, F., 2003. Genetics: influence of TOR kinase on lifespan in *C. elegans*. *Nature* 426, 620.
- Viswanathan, M., Kim, S.K., Berdichevsky, A., Guarente, L., 2005. A role for SIR-2.1 regulation of ER stress response genes in determining *C. elegans* life span. *Dev. Cell* 9, 605–615.
- Wallace, D.C., 2005. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. *Annu. Rev. Genet.* 39, 359–407.
- Wei, M., Fabrizio, P., Hu, J., Ge, H., Cheng, C., Li, L., Longo, V.D., 2008. Life span extension by calorie restriction depends on Rm15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. *PLoS Genet.* 4, e13.
- Weindruch, R., Walford, R.L., 1988. The Retardation of Aging and Disease by Dietary Restriction. Charles C Thomas, Springfield, Illinois.
- Wenz, T., Diaz, F., Spiegelman, B.M., Moraes, C.T., 2008. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. *Cell Metabol.* 8, 249–256.
- Weydt, P., Pineda, V.V., Torrence, A.E., Libby, R.T., Satterfield, T.F., Lazarowski, E.R., Gilbert, M.L., Morton, G.J., Bammler, T.K., Strand, A.D., Cui, L., Beyer, R.P., Easley, C.N., Smith, A.C., Krainc, D., Luquet, S., Sweet, I.R., Schwartz, M.W., La Spada, A.R., 2006. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. *Cell Metabol.* 4, 349–362.
- Williams, A.D., Carey, M.F., Selig, S., Hayes, A., Krum, H., Patterson, J., Toia, D., Hare, D.L., 2007. Circuit resistance training in chronic heart failure improves skeletal muscle mitochondrial ATP production rate—a randomized controlled trial. *J. Cardiac Fail.* 13, 79–85.
- Winder, W.W., Taylor, E.B., Thomson, D.M., 2006. Role of AMP-activated protein kinase in the molecular adaptation to endurance exercise. *Med. Sci. Sports Exerc.* 38, 1945–1949.
- Winder, W.W., Holmes, B.F., Rubink, D.S., Jensen, E.B., Chen, M., Holloszy, J.O., 2000. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. *J. Appl. Physiol.* 88, 2219–2226.
- Wood, J.G., Rogina, B., Lavu, S., Howitz, K., Helfand, S.L., Tatar, M., Sinclair, D., 2004. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. *Nature* 430, 686–689.
- Wu, H., Kanatous, S.B., Thurmond, F.A., Gallardo, T., Isotani, E., Bassel-Duby, R., Williams, R.S., 2002. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. *Science* 296, 349–352.
- Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R.C., Spiegelman, B.M., 1999. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. *Cell* 98, 115–124.
- Wullschlegel, S., Loewith, R., Hall, M.N., 2006. TOR signaling in growth and metabolism. *Cell* 124, 471–484.
- Yang, H., Yang, T., Baur, J.A., Perez, E., Matsui, T., Carmona, J.J., Lamming, D.W., Souza-Pinto, N.C., Bohr, V.A., Rosenzweig, A., de Cabo, R., Sauve, A.A., Sinclair, D.A., 2007. Nutrient-sensitive mitochondrial NAD⁺ levels dictate cell survival. *Cell* 130, 1095–1107.
- Yen, T.C., Chen, Y.S., King, K.L., Yeh, S.H., Wei, Y.H., 1989. Liver mitochondrial respiratory functions decline with age. *Biochem. Biophys. Res. Commun.* 165, 944–1003.
- Ying, W., 2006. NAD⁺ and NADH in cellular functions and cell death. *Front Biosci.* 11, 3129–3148.
- Zahn, J.M., Sonu, R., Vogel, H., Crane, E., Mazan-Mamczarz, K., Rabkin, R., Davis, R.W., Becker, K.G., Owen, A.B., Kim, S.K., 2006. Transcriptional profiling of aging in human muscle reveals a common aging signature. *PLoS Genet.* 2, e115.
- Zahn, J.M., Poosala, S., Owen, A.B., Ingram, D.K., Lustig, A., Carter, A., Weeraratna, A.T., Taub, D.D., Gorospe, M., Mazan-Mamczarz, K., Lakatta, E.G., Boheler, K.R., Xu, X., Mattson, M.P., Falco, G., Ko, M.S., Schlessinger, D., Firman, J., Kummerfeld, S.K., Wood 3rd, W.H., Zonderman, A.B., Kim, S.K., Becker, K.G., 2007. AGEMAP: a gene expression database for aging in mice. *PLoS Genet.* 3, e201.
- Zang, M., Xu, S., Maitland-Toolan, K.A., Zuccollo, A., Hou, X., Jiang, B., Wierzbicki, M., Verbeuren, T.J., Cohen, R.A., 2006. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. *Diabetes* 55, 2180–2191.
- Zhao, Q., Wang, J., Levichkin, I.V., Stasinopoulos, S., Ryan, M.T., Hoogenraad, N.J., 2002. A mitochondrial specific stress response in mammalian cells. *EMBO J.* 21, 4411–4419.
- Zhu, M., Miura, J., Lu, L.X., Bernier, M., DeCabo, R., Lane, M.A., Roth, G.S., Ingram, D.K., 2004. Circulating adiponectin levels increase in rats on caloric restriction: the potential for insulin sensitization. *Exp. Gerontol.* 39, 1049–1059.
- Zong, H., Ren, J.M., Young, L.H., Pypaert, M., Mu, J., Birnbaum, M.J., Shulman, G.I., 2002. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. *Proc. Natl. Acad. Sci. U.S.A.* 99, 15983–15987.